<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Thrombopoietin mimetics for patients with myelodysplastic syndromes - Dodillet, H - 2017 | Cochrane Library</title> <meta content="Thrombopoietin mimetics for patients with myelodysplastic syndromes - Dodillet, H - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009883.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Thrombopoietin mimetics for patients with myelodysplastic syndromes - Dodillet, H - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009883.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009883.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Thrombopoietin mimetics for patients with myelodysplastic syndromes" name="citation_title"/> <meta content="Helga Dodillet" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Karl‐Anton Kreuzer" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Ina Monsef" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Nicole Skoetz" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="nicole.skoetz@uk-koeln.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD009883.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/09/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009883.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009883.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009883.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Azacitidine [analogs &amp; derivatives, therapeutic use]; Benzoates [*therapeutic use]; Blood Transfusion [statistics &amp; numerical data]; Decitabine; Hemorrhage [chemically induced]; Hydrazines [*therapeutic use]; Lenalidomide; Leukemia, Myeloid, Acute [etiology]; Myelodysplastic Syndromes [*complications, mortality]; Pyrazoles [*therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc [*therapeutic use]; Recombinant Fusion Proteins [*therapeutic use]; Thalidomide [analogs &amp; derivatives, therapeutic use]; Thrombocytopenia [*drug therapy, etiology]; Thrombopoietin [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009883.pub2&amp;doi=10.1002/14651858.CD009883.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009883\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009883\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","ru","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009883.pub2",title:"Thrombopoietin mimetics for patients with myelodysplastic syndromes",firstPublishedDate:"Sep 30, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009883.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009883.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009883.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009883.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009883.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009883.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009883.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009883.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009883.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009883.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2292 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009883.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-sec-0085"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-sec-0030"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-sec-0079"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/appendices#CD009883-sec-0090"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/table_n/CD009883StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/table_n/CD009883StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Thrombopoietin mimetics for patients with myelodysplastic syndromes</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/information#CD009883-cr-0002">Helga Dodillet</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/information#CD009883-cr-0003">Karl‐Anton Kreuzer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/information#CD009883-cr-0004">Ina Monsef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009883.pub2/information#CD009883-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Nicole Skoetz</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/information/en#CD009883-sec-0095">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 September 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009883.pub2">https://doi.org/10.1002/14651858.CD009883.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009883-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009883-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009883-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009883-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009883-abs-0001" lang="en"> <section id="CD009883-sec-0001"> <h3 class="title" id="CD009883-sec-0001">Background</h3> <p>Myelodysplastic syndrome (MDS) is one of the most frequent haematologic malignancies of the elderly population and characterised by progenitor cell dysplasia with ineffective haematopoiesis and a high rate of transformation to acute myeloid leukaemia (AML). Thrombocytopenia represents a common problem for patients with MDS. ranging from mild to serious bleeding events and death. To manage thrombocytopenia, the current standard treatment includes platelet transfusion, unfortunately leading to a range of side effects. Thrombopoietin (TPO) mimetics represent an alternative treatment option for MDS patients with thrombocytopenia. However, it remains unclear, whether TPO mimetics influence the increase of blast cells and therefore to premature progression to AML. </p> </section> <section id="CD009883-sec-0002"> <h3 class="title" id="CD009883-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of thrombopoietin (TPO) mimetics for patients with MDS. </p> </section> <section id="CD009883-sec-0003"> <h3 class="title" id="CD009883-sec-0003">Search methods</h3> <p>We searched for randomised controlled trials in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 2000 to August 2017), trials registries (ISRCTN, EU clinical trials register and clinicaltrials.gov) and conference proceedings. We did not apply any language restrictions. Two review authors independently screened search results, disagreements were solved by discussion. </p> </section> <section id="CD009883-sec-0004"> <h3 class="title" id="CD009883-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials comparing TPO mimetics with placebo, no further treatment or another TPO mimetic in patients with MDS of all risk groups, without gender, age or ethnicity restrictions. Additional chemotherapeutic treatment had to be equal in both arms. </p> </section> <section id="CD009883-sec-0005"> <h3 class="title" id="CD009883-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed the quality of trials, disagreements were resolved by discussion. Risk ratio (RR) was used to analyse mortality during study, transformation to AML, incidence of bleeding events, transfusion requirement, all adverse events, adverse events &gt;= grade 3, serious adverse events and platelet response. Overall survival (OS) and progression‐free survival (PFS) have been extracted as hazard ratios, but could not be pooled as results were reported in heterogenous ways. Health‐related quality of life and duration of thrombocytopenia would have been analysed as standardised mean differences, but no trial reported these outcomes. </p> </section> <section id="CD009883-sec-0006"> <h3 class="title" id="CD009883-sec-0006">Main results</h3> <p>We did not identify any trial comparing one TPO mimetic versus another. We analysed six eligible trials involving 746 adult patients. All trials were reported as randomised and double‐blind trials including male and female patients. Two trials compared TPO mimetics (romiplostim or eltrombopag) with placebo, one trial evaluated eltrombopag in addition to the hypomethylating agent azacitidine, two trials analysed romiplostim additionally to a hypomethylating agent (azacitidine or decitabine) and one trial evaluated romiplostim in addition to the immunomodulatory drug lenalidomide. There are more data on romiplostim (four included, completed, full‐text trials) than on eltrombopag (two trials included: one full‐text publication, one abstract publication). Due to small sample sizes and imbalances in baseline characteristics in three trials and premature termination of two studies, we judged the potential risk of bias of all included trials as high. </p> <p>Due to heterogenous reporting, we were not able to pool data for OS. Instead of that, we analysed mortality during study. There is little or no evidence for a difference in mortality during study for thrombopoietin mimetics compared to placebo (RR 0.97, 95% confidence interval (CI) 0.73 to 1.27, N = 6 trials, 746 patients, <i>low‐quality evidence</i> ). It is unclear whether the use of TPO mimetics induces an acceleration of transformation to AML (RR 1.02, 95% CI 0.59 to 1.77, N = 5 trials, 372 patients, <i>very low‐quality evidence</i> ).Thrombopoietin mimetics probably improve the incidence of all bleeding events (RR 0.92, 95% CI 0.86 to 0.99, N = 5 trials, 390 patients, <i>moderate‐quality evidence</i> ). This means that in the study population, 713 out of 1000 in the placebo arm will have a bleeding event, compared to 656 of 1000 (95% CI 613 to 699) in the TPO mimetics arm. There is little or no evidence for a difference that TPO mimetics significantly diminish the rate of transfusion requirement (RR 0.83, 95% CI 0.66 to 1.05, N = 4 trials, 358 patients, <i>low‐quality evidence</i>). No studies were found that looked at quality of life or duration of thrombocytopenia. </p> <p>There is no evidence that patients given TPO mimetics suffer more all adverse events (RR 1.01, 95% CI 0.96 to 1.07, N = 5 trials, 390 patients, <i>moderate‐quality evidence</i> ). There is uncertainty whether the number of serious adverse events decrease under therapy with TPO mimetics (RR 0.89, 95% CI 0.54 to 1.46, N = 4 trials, 356 patients, <i>very low‐quality evidence</i>). </p> <p>We identified one ongoing study and one study marked as completed (March 2015), but without publication of results for MDS patients (only results reported for AML and MDS patients together). Both studies evaluate MDS patients receiving eltrombopag in comparison to placebo. </p> </section> <section id="CD009883-sec-0007"> <h3 class="title" id="CD009883-sec-0007">Authors' conclusions</h3> <p>No trial evaluated one TPO mimetic versus another.</p> <p>Six trials including adult patients analysed one TPO mimetic versus placebo, sometimes combined with standard therapy in both arms. Given the uncertainty of the quality of evidence, meta‐analyses show that there is little or no evidence for a difference in mortality during study and premature progress to AML. However, these assumptions have to be further explored. Treatment with TPO mimetics resulted in a lower number of MDS patients suffering from bleeding events.There is no evidence for a difference between study groups regarding transfusion requirement. Enlarged sample sizes and a longer follow‐up of future trials should improve the estimate of safety and efficacy of TPO mimetics, moreover health‐related quality of life should be evaluated. As two ongoing studies currently investigate eltrombopag (one already completed, but without published results), we are awaiting results for this drug. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009883-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009883-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009883-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009883-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009883-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009883-abs-0006">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009883-abs-0003" lang="en"> <h3>Thrombopoietin mimetics for patients with myelodysplastic syndromes</h3> <p><b>Background</b> </p> <p>Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders associated with anaemia, bleedings or infections as a result of peripheral cytopenias and a premature progress to acute myeloid leukaemia (AML). Patients mainly suffer at an elderly age. Bone marrow transplantation remains the only curative option. Thrombocytopenia represents a life‐threatening complication in the course of illness and alternative treatment options to platelet transfusion are limited.The introduction of TPO mimetics (raising platelet counts by imitating the effect of human TPO) in the treatment of MDS may extend the range of therapy. </p> <p><b>Review question</b> </p> <p>With this review we aimed to take a closer look at TPO mimetics in the treatment of MDS patients. We intended to focus on changes of overall survival, mortality during study, transformation to AML, incidence of bleeding events, transfusion requirement, health‐related quality of life, all adverse events, and serious adverse events to explore the effect of TPO mimetics. </p> <p><b>Study characteristics</b> </p> <p>We searched medical databases such as Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, conference proceedings and study registries (January 2000 to August 2017). No trial evaluated one TPO mimetic (romiplostim or eltrombopag) versus another. We found eight eligible trials (six included, two ongoing, one of which is completed but without final results for MDS patients) and we included 746 adult patients in our review. The trials were randomised, double‐blinded and used either romiplostim or eltrombopag versus placebo. In four trials hypomethylating agents or immunomodulatory drugs were administered in combination to romiplostim or eltrombopag. Only adults were included. </p> <p><b>Key results</b> </p> <p>A meta‐analysis of overall survival data was not possible, since data were too heterogeneous to pool. Instead of that, we analysed mortality data. There was no evidence for a difference between TPO mimetics and placebo in terms of mortality during study, transformation to AML, transfusion requirement, adverse events and serious adverse events. Thrombopoietin mimetics probably decrease the number of patients having bleeding events. In the study population, 713 out of 1000 in the placebo arm had a bleeding event, compared to 656 of 1000 (95% confidence interval (CI) 613 to 699) in the TPO mimetics arm. No trial evaluated health‐related quality. </p> <p><b>Quality of evidence</b> </p> <p>The quality of evidence for the outcomes incidence of bleeding events and all adverse events is moderate due to high risk of bias (small sample sizes and imbalances in baseline characteristics in three trials, premature closure of two trials, selective reporting in one trial, industrial sponsorship). The quality of evidence for the outcomes mortality during study and transfusion requirements is low, due to imprecision through small number of events and high risk of bias. It is very low for the outcomes transformation to AML and serious adverse events, because of very small number of events, high risk of bias and heterogeneity between trials. </p> <p><b>Conclusion</b> </p> <p>Although this systematic review reveals a potential patient‐relevant benefit regarding decreasing bleeding events for evaluated adult patients, future trials should focus on outcomes referring to safety, efficacy and quality of life aspects of TPO mimetics to test their everyday usage. The assumption of premature progress to AML could not be clearly verified. Because of the low number of included trials and small sample sizes, uncertainties of the findings in this review exist and demand further investigation with more trials and participants and longer follow‐up periods. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009883-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009883-sec-0085"></div> <h3 class="title" id="CD009883-sec-0086">Implications for practice</h3> <section id="CD009883-sec-0086"> <p>No study evaluated one thrombopoietin (TPO) mimetic versus another.</p> <p>Six trials in adult patients evaluated one TPO mimetic versus placebo or in addition to standard therapy compared to standard therapy only. At this stage there is little or no evidence to provide, that TPO mimetics represent an effective therapeutical option for myelodysplastic syndrome (MDS) patients with thrombocytopenia in everyday practice. Due to the uncertainty, given the quality of the evidence at present, there is little or no evidence for a difference for a prolonged overall survival (OS) or a lower mortality rate when treated with TPO mimetics compared to placebo. Although this meta‐analysis did not show statistically significant results that TPO mimetic treatment leads to premature AML‐progression, this might be the case and requires further investigations. Compared to placebo‐treated patients, less bleeding events occurred under therapy with TPO mimetics. The use of romiplostim or eltrombopag might reduce the requirement of platelet transfusion and therefore lower all, partly fatal transfusion‐associated risks. There might be more serious adverse events when romiplostim is solely administered without any concomitant agents, whereas a combination of TPO mimetics and immunomodulatory agents e.g. lenalidomide seem to reduce the incidence of serious adverse events. </p> </section> <h3 class="title" id="CD009883-sec-0087">Implications for research</h3> <section id="CD009883-sec-0087"> <p>More studies with longer follow‐up periods and a larger number of participants are needed to produce solid results and therefore determine the effect of TPO mimetics. We have to acquire more evidence in terms of the safety, efficacy and quality of life aspects of these agents. Especially the impact of TPO mimetics regarding the potential of influencing premature AML transformation should be further investigated, as AML progression represents a dreaded event for MDS patients. It is a fact that hypomethylating agents also cause haematologic improvement. Therefore, single‐agent trials focusing on TPO mimetics alone should be performed to explore the individual benefit of these agents regarding platelet response, bleeding events and transfusion requirements.As long as TPO mimetics are not proven to provide any benefit compared to placebo or no treatment only, head‐to‐head comparisons are not necessary. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009883-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009883-sec-0015"></div> <div class="table" id="CD009883-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Thrombopoietin mimetics compared to placebo for patients with myelodysplastic syndromes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Thrombopoietin mimetics compared to placebo for patients with myelodysplastic syndromes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Adult patients with myelodysplastic syndromes and thrombocytopenia<br/> <b>Setting:</b> Inpatient or outpatient. The duration of studies ranged from four 28‐day cycles to 6 months and &gt; 58 weeks<br/> <b>Intervention:</b> Thrombopoietin mimetics or thrombopoietin plus standard therapy; thrombopoietin mimetics: </p> <p> <ul id="CD009883-list-0001"> <li> <p>romiplostim: 500 µg or 750 µg</p> </li> <li> <p>eltrombopag: 200 mg/day (100 mg/day for East Asians), adjusted by 100 mg increments (50 mg for East Asians) to a maximum 300 mg/day (150 mg/day in East Asias) or 50 mg daily initial dose, adjusted every 2 weeks based on platelet response up to a maximum of 300 mg once daily (150 mg for East Asian patients) for 6 months as an oral tablet </p> </li> </ul> </p> <p><b>Comparison:</b> Placebo or placebo plus standard therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Thrombopoietin mimetics</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall survival</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>282 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> did not provide 95% CI, data could not be meta‐analysed. </p> <p><a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>: OS 58‐weeks follow up: 18% of romiplostim patients died and 20.5% of placebo patients (HR 0.86, 95% CI 0.48 to 1.56). </p> <p><a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>: median OS: 34 weeks for eltrombopag patients and 15.4 weeks for placebo‐treated patients (HR 0.70, CI not provided) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality during study</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.73 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>746<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1; 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>242 per 1.000<br/> (182 to 316) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Transformation to AML</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/> (0.59 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>372<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1.000<br/> (65 to 195) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of bleeding events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/> (0.86 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>390<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>713 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>656 per 1.000</p> <p>(613 to 699)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Transfusion requirement</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/> (0.66 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>358<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>508 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>422 per 1.000<br/> (335 to 534) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01</p> <p>(0.96 to 1.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>390<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>912 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>921 per 1.000<br/> (875 to 976) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.54 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>356<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2 ,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>387 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>344 per 1.000<br/> (209 to 564) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Small number of events (&lt;200) resulting in downgrading 1 point due to imprecision </p> <p><sup>2</sup> High risk of bias due to small sample sizes and imbalances in baseline characteristics in three trials, premature closure of two trials, selective reporting in one trial, and industrial sponsorship </p> <p><sup>3</sup> Very small number of events (&lt;50) resulting in downgrading 2 points due to imprecision </p> <p><sup>4</sup> Heterogeneity between studies resulting in downgrading in 1 point </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009883-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009883-sec-0016"></div> <section id="CD009883-sec-0017"> <h3 class="title" id="CD009883-sec-0017">Description of the condition</h3> <section id="CD009883-sec-0018"> <h4 class="title">Epidemiology of myelodysplastic syndromes (MDS)</h4> <p>Myelodysplastic syndromes (MDS) are a heterogeneous group of haematological diseases that are characterised by a uni‐ or multilineage dysplasia of haematological stem cells. MDS is a rare disease of the elderly population. The overall incidence of the disease is about 4 to 7 per 100,000 people, whereas 20 to 50 per 100,000 people over the age of 70 years are affected (<a href="./references#CD009883-bbs2-0022" title="Della PortaMG , MalcovatiL , StruppC , AmbaglioI , KuendgenA , ZippererE , et al. Risk stratification based on both disease status and extra‐hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica2010;96(3):441‐9. ">Della Porta 2010</a>; <a href="./references#CD009883-bbs2-0031" title="GreenbergPL , AttarE , BattiwallaM , BennettJM , BloomfieldCD , DeCastroCM , et al. Myelodysplastic syndrome. NCCN Clinical Practice Guidelines in Oncology. V.2.2011. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. ">Greenberg 2011</a>; <a href="./references#CD009883-bbs2-0059" title="SekeresMA . Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. Journal of the National Comprehensive Cancer Network2011;9:57‐63. ">Sekeres 2011b</a>). Approximately 85% of all patients with MDS are over 60 years when first diagnosed (<a href="./references#CD009883-bbs2-0027" title="GoldbergS L , ChenE , CorralM , GuoA , Mody‐PatelN , PecoraA L , et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. Journal of Clinical Oncology2010;28(17):2847‐52. ">Goldberg 2010</a>). In general, MDS is characterised by myeloid, erythroid or megakaryocytic dysplasia, or a combination of dysplasias, associated with ineffective haematopoiesis and a high rate of transformation to acute myeloid leukaemia (AML) in approximately 20% of patients with MDS (<a href="./references#CD009883-bbs2-0052" title="NimerSD . Myelodysplastic syndromes. Blood2008;111(10):4841‐51. ">Nimer 2008</a>; <a href="./references#CD009883-bbs2-0064" title="VardimanJW , ThieleJ , ArberDA , BrunningRD , BorowitzMJ , PorwitA , et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood2009;114(5):937‐51. ">Vardiman 2009</a>). </p> </section> <section id="CD009883-sec-0019"> <h4 class="title">Classification of MDS</h4> <p>Two systems are commonly used to define haematopoietic malignancies. The French‐American‐British classification, introduced in 1976, is based on morphological and cytochemical methods (<a href="./references#CD009883-bbs2-0016" title="BennettJM , CatovskyD , DanielMT , FlandrinG , GaltonDA , GralnickHR , et al. Proposals for the classification of the acute leukaemias. French‐American‐British (FAB) Co‐operative Group. British Journal of Haematology1976;33:451‐8. ">Bennett 1976</a>). It subcategorises MDS into five entities and sets the threshold between high‐grade MDS and AML at 30% blasts in the bone marrow. The World Health Organization (WHO) classification, introduced in 1999 and revised in 2008, uses morphology and newer prognostic factors such as karyotype and clinical features to define the different entities (<a href="./references#CD009883-bbs2-0032" title="HarrisNL , JaffeES , DieboldJ , FlandrinG , Muller‐HermelinkHK , VardimanJ , et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting‐Airlie House, Virginia. Journal of Clinical Oncology1999;17:3835‐49. ">Harris 1999</a>; <a href="./references#CD009883-bbs2-0064" title="VardimanJW , ThieleJ , ArberDA , BrunningRD , BorowitzMJ , PorwitA , et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood2009;114(5):937‐51. ">Vardiman 2009</a>). It distinguishes between five entities and 11 subtypes of MDS, and the threshold for the diagnosis of AML has been lowered to &gt; 20% blasts (<a href="./references#CD009883-bbs2-0032" title="HarrisNL , JaffeES , DieboldJ , FlandrinG , Muller‐HermelinkHK , VardimanJ , et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting‐Airlie House, Virginia. Journal of Clinical Oncology1999;17:3835‐49. ">Harris 1999</a>; <a href="./references#CD009883-bbs2-0064" title="VardimanJW , ThieleJ , ArberDA , BrunningRD , BorowitzMJ , PorwitA , et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood2009;114(5):937‐51. ">Vardiman 2009</a>). </p> </section> <section id="CD009883-sec-0020"> <h4 class="title">Prognosis of MDS</h4> <p>The International Prognostic Scoring System (IPSS) is the most widely used risk assessment system to evaluate the prognosis of MDS. The tool is based on the percentage of blasts in the bone marrow, the number of cytopenias and the karyotype, and categorises newly diagnosed patients into the following four groups: low, intermediate‐1, intermediate‐2 and high risk (<a href="./references#CD009883-bbs2-0029" title="GreenbergP , CoxC , LeBeauMM , FenauxP , MorelP , SanzG , et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood1997;89(6):2079‐88. ">Greenberg 1997</a>). These prognostic groups are associated with a median survival of 5.7 years (low risk), 3.5 years (intermediate‐1 risk), 1.2 years (intermediate‐2 risk) and 0.4 years (high risk) (<a href="./references#CD009883-bbs2-0029" title="GreenbergP , CoxC , LeBeauMM , FenauxP , MorelP , SanzG , et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood1997;89(6):2079‐88. ">Greenberg 1997</a>). </p> </section> <section id="CD009883-sec-0021"> <h4 class="title">Clinical presentation focusing on thrombocytopenia</h4> <p>Clinical symptoms of patients with MDS are related to the occurring cytopenias (anaemia, neutropenia (decrease in white blood cells, specifically neutrophils), and thrombocytopenia (decrease in the number of blood platelets)) that arise from the ineffective haematopoiesis. Often patients present with symptoms of anaemia such as fatigue, asthenia and dyspnoea, accompanied by infections due to neutropenia and prolonged bleeding time or bleeding events because of thrombocytopenia (<a href="./references#CD009883-bbs2-0052" title="NimerSD . Myelodysplastic syndromes. Blood2008;111(10):4841‐51. ">Nimer 2008</a>). </p> <p>In 2007 Kantarjian and colleagues performed a systematic review to summarise the available information regarding the incidence and impact of thrombocytopenia in patients with MDS. It demonstrated that thrombocytopenia (defined as platelet count &lt; 100 x 10<sup>9</sup>/L) is a common clinical problem in MDS patients with a prevalence of 65% (range 23% to 93%) in untreated patients at baseline (<a href="./references#CD009883-bbs2-0039" title="KantarjianH , GilesF , ListA , LyonsR , SekeresMA , PierceS , et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer2007;109:1705‐14. ">Kantarjian 2007</a>). An additional problem is the iatrogenically‐induced thrombocytopenia through currently available therapeutics in the treatment of MDS such as hypomethylation agents (i.e. azacitidine, decitabine), or lenalidomide (<a href="./references#CD009883-bbs2-0038" title="KantarjianH , IssaJP , RosenfeldCS , BennettJM , AlbitarM , DiPersioJ , et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer2006; Vol. 106, issue 8:1794‐803. ">Kantarjian 2006</a>; <a href="./references#CD009883-bbs2-0046" title="ListA , DewaldG , BennettJ , GiagounidisA , RazaA , FeldmanE , et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine2006;355:1456‐65. ">List 2006a</a>). Randomised studies reported thrombocytopenia grade 3 or 4 in 70% to 74% of the patients receiving azacitidine (<a href="./references#CD009883-bbs2-0025" title="FenauxP , MuftiGJ , Hellstrom‐LindbergE , SantiniV , FinelliC , GiagounidisA , et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher‐risk myelodysplastic syndromes: a randomised, open‐label, phase III study. Lancet Oncology2009;10(3):223‐32. ">Fenaux 2009</a>; <a href="./references#CD009883-bbs2-0057" title="SantiniV , AlessandrinoPE , AngelucciE , BarosiG , BillioA , DiMaioM , et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leukemia Research2010;34:1576‐88. ">Santini 2010</a>), 85% of the patients with decitabine (<a href="./references#CD009883-bbs2-0038" title="KantarjianH , IssaJP , RosenfeldCS , BennettJM , AlbitarM , DiPersioJ , et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer2006; Vol. 106, issue 8:1794‐803. ">Kantarjian 2006</a>) and 54.7% of the patients with lenalidomide (<a href="./references#CD009883-bbs2-0046" title="ListA , DewaldG , BennettJ , GiagounidisA , RazaA , FeldmanE , et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine2006;355:1456‐65. ">List 2006a</a>). </p> <p>The most important clinical complications caused by thrombocytopenia are bleeding events and death. The reported incidence of bleeding in MDS patients ranges from 3% to 53% (<a href="./references#CD009883-bbs2-0039" title="KantarjianH , GilesF , ListA , LyonsR , SekeresMA , PierceS , et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer2007;109:1705‐14. ">Kantarjian 2007</a>). These bleeding complications might be less severe such as petechiae, gingival bleeding (bleeding from the gums) or haematoma, but can also be serious if gastrointestinal, intracranial, pulmonary or retinal haemorrhages occur (<a href="./references#CD009883-bbs2-0019" title="DayyaniF , ConleyAP , StromSS , StevensonW , CortesJE , BorthakurG , et al. Cause of death in patients with lower‐risk myelodysplastic syndrome. Cancer2010; Vol. 116, issue 9:2174‐9. ">Dayyani 2010</a>; <a href="./references#CD009883-bbs2-0051" title="NeukirchenJ , BlumS , KuendgenA , StruppC , AivadoM , HaasR , et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. European Journal of Haematology2009;83(5):477‐82. ">Neukirchen 2009</a>). The frequency of haemorrhagic deaths in patients with MDS ranges from 14% to 24% (<a href="./references#CD009883-bbs2-0039" title="KantarjianH , GilesF , ListA , LyonsR , SekeresMA , PierceS , et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer2007;109:1705‐14. ">Kantarjian 2007</a>). </p> </section> </section> <section id="CD009883-sec-0022"> <h3 class="title" id="CD009883-sec-0022">Description of the intervention</h3> <section id="CD009883-sec-0023"> <h4 class="title">General treatment approaches of MDS</h4> <p>Patients with clinically relevant cytopenia can be stratified into two major risk groups, the relatively lower‐risk patients (IPSS: low risk, intermediate‐1‐risk) and the higher‐risk patients (IPSS: high risk, intermediate‐2‐risk) (<a href="./references#CD009883-bbs2-0017" title="BowenD , CulliganD , JowittS , KelseyS , MuftiG , OscierD , et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. British Journal of Haematology2003;120(2):187‐200. ">Bowen 2003</a>; <a href="./references#CD009883-bbs2-0031" title="GreenbergPL , AttarE , BattiwallaM , BennettJM , BloomfieldCD , DeCastroCM , et al. Myelodysplastic syndrome. NCCN Clinical Practice Guidelines in Oncology. V.2.2011. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. ">Greenberg 2011</a>). In lower‐risk patients with MDS, supportive care, meaning red blood or platelet transfusion, antibiotics and hematopoietic growth factors, is the main treatment option, but the administration of additional treatment with hypomethylation agents or immunosuppressive therapy might be considered (<a href="./references#CD009883-bbs2-0026" title="FeyMF , Dreyling M and ESMO Guidelines Working Group. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Annals of Oncology2010;21 Suppl 5:158‐61. ">Fey 2010</a>; <a href="./references#CD009883-bbs2-0028" title="GotzeK , PlatzbeckerU , GiagounidisA , HaaseD , LubbertM , AulC , et al. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Annals of Hematology2010;89:841‐50. ">Gotze 2010</a>; <a href="./references#CD009883-bbs2-0031" title="GreenbergPL , AttarE , BattiwallaM , BennettJM , BloomfieldCD , DeCastroCM , et al. Myelodysplastic syndrome. NCCN Clinical Practice Guidelines in Oncology. V.2.2011. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. ">Greenberg 2011</a>; <a href="./references#CD009883-bbs2-0057" title="SantiniV , AlessandrinoPE , AngelucciE , BarosiG , BillioA , DiMaioM , et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leukemia Research2010;34:1576‐88. ">Santini 2010</a>). Higher‐risk patients with MDS should receive allogenic stem cell transplantation (alloSCT), which is the only curative treatment for MDS patients. If they are not eligible for allogenic stem cell transplantation (due to patient's age, performance status and presence of major comorbid conditions) or lacking an available donor, there are different recommended alternatives that include hypomethylation agents, other low‐intensive chemotherapeutics and high‐intensive chemotherapy regimens, with or without autologous stem cell transplantation (<a href="./references#CD009883-bbs2-0026" title="FeyMF , Dreyling M and ESMO Guidelines Working Group. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Annals of Oncology2010;21 Suppl 5:158‐61. ">Fey 2010</a>; <a href="./references#CD009883-bbs2-0028" title="GotzeK , PlatzbeckerU , GiagounidisA , HaaseD , LubbertM , AulC , et al. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Annals of Hematology2010;89:841‐50. ">Gotze 2010</a>; <a href="./references#CD009883-bbs2-0031" title="GreenbergPL , AttarE , BattiwallaM , BennettJM , BloomfieldCD , DeCastroCM , et al. Myelodysplastic syndrome. NCCN Clinical Practice Guidelines in Oncology. V.2.2011. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. ">Greenberg 2011</a>; <a href="./references#CD009883-bbs2-0057" title="SantiniV , AlessandrinoPE , AngelucciE , BarosiG , BillioA , DiMaioM , et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leukemia Research2010;34:1576‐88. ">Santini 2010</a>). </p> </section> <section id="CD009883-sec-0024"> <h4 class="title">Treatment options focusing on thrombocytopenia</h4> <p>In general, clinical practice guidelines recommend platelet transfusion to manage severe thrombocytopenia or thrombocytopenic bleeding (<a href="./references#CD009883-bbs2-0026" title="FeyMF , Dreyling M and ESMO Guidelines Working Group. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Annals of Oncology2010;21 Suppl 5:158‐61. ">Fey 2010</a>; <a href="./references#CD009883-bbs2-0031" title="GreenbergPL , AttarE , BattiwallaM , BennettJM , BloomfieldCD , DeCastroCM , et al. Myelodysplastic syndrome. NCCN Clinical Practice Guidelines in Oncology. V.2.2011. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. ">Greenberg 2011</a>; <a href="./references#CD009883-bbs2-0057" title="SantiniV , AlessandrinoPE , AngelucciE , BarosiG , BillioA , DiMaioM , et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leukemia Research2010;34:1576‐88. ">Santini 2010</a>). Furthermore, aminocaproic acid or other antifibrinolytic agents may be considered for bleeding refractory to platelet transfusion or profound thrombocytopenia (<a href="./references#CD009883-bbs2-0031" title="GreenbergPL , AttarE , BattiwallaM , BennettJM , BloomfieldCD , DeCastroCM , et al. Myelodysplastic syndrome. NCCN Clinical Practice Guidelines in Oncology. V.2.2011. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. ">Greenberg 2011</a>). </p> <p>Although platelet transfusions are effective to increase platelet counts, they are associated with a range of risks including transfusion‐related fever, allergic reactions, infections with bacteria or viruses, pulmonary disease or alloimmunisation (<a href="./references#CD009883-bbs2-0040" title="KantarjianH , FenauxP , SekeresMA , BeckerPS , BoruchovA , BowenD , et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology2009;28(3):437‐44. ">Kantarjian 2009</a>; <a href="./references#CD009883-bbs2-0048" title="McCulloughJ . Current issues with platelet transfusion in patients with cancer. Seminars in Hematology2000;37:3‐10. ">McCullough 2000</a>; <a href="./references#CD009883-bbs2-0049" title="MelchertM , ListA . Targeted therapies in myelodysplastic syndrome. Seminars in Hematology2008;45(1):31‐8. ">Melchert 2008</a>). Platelet alloimmunisation occurs when a patient has formed antibodies against donor platelets. It leads to refractoriness of platelet transfusion with a significantly lower platelet count after transfusion than expected. After multiple platelet transfusions 5% to 15% of the patients become refractory (<a href="./references#CD009883-bbs2-0056" title="RebullaP . A mini‐review on platelet refractoriness. Haematologica2005;90:247‐53. ">Rebulla 2005</a>). </p> <p>Alternative treatment options to platelet transfusion are limited. Clinical studies evaluated different approaches including immunosuppressive agents such as cyclosporine (<a href="./references#CD009883-bbs2-0060" title="SloandEM , GreenbergP , WuC , YoungNS , BarrettJ . Immunosuppressive treatment is associated with durable responses and a survival advantage in younger patients with int‐1 myelodysplastic syndrome. Blood2005;106:2519. ">Sloand 2005</a>) and antithymocyte globulin (<a href="./references#CD009883-bbs2-0020" title="DeegHJ , JiangPY , HolmbergLA , ScottB , PetersdorfEW , AppelbaumFR . Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leukemia Research2004;28:1177‐80. ">Deeg 2004</a>). Due to the limited efficacy of these agents, clinical practice guidelines mention immunosuppressive therapy as a treatment option only for patients with refractory severe thrombocytopenia (<a href="./references#CD009883-bbs2-0026" title="FeyMF , Dreyling M and ESMO Guidelines Working Group. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Annals of Oncology2010;21 Suppl 5:158‐61. ">Fey 2010</a>; <a href="./references#CD009883-bbs2-0031" title="GreenbergPL , AttarE , BattiwallaM , BennettJM , BloomfieldCD , DeCastroCM , et al. Myelodysplastic syndrome. NCCN Clinical Practice Guidelines in Oncology. V.2.2011. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. ">Greenberg 2011</a>). Currently, thrombopoietin mimetics (i.e. romiplostim and eltrombopag) are in the focus of clinical research. </p> </section> </section> <section id="CD009883-sec-0025"> <h3 class="title" id="CD009883-sec-0025">How the intervention might work</h3> <p>Thrombopoietin is a glycoprotein, primarily synthesised by the liver and kidney. It is the major regulator of both megakaryocytopoiesis and thrombopoiesis. After binding to the thrombopoietin receptor (that is expressed at the pluripotential stem cells, early progenitor cells, the megakaryocyte colony‐forming cells and early megakaryocyte progenitors) thrombopoietin launches a number of signal transduction processes that initiate cell proliferation, ramp up cell differentiation and stimulate an anti‐apoptotic cascade (<a href="./references#CD009883-bbs2-0042" title="KaushanskyK . Lineage‐specific hematopoietic growth factors. New England Journal of Medicine2006;354:2034‐45. ">Kaushansky 2006</a>; <a href="./references#CD009883-bbs2-0043" title="KuterDJ . New thrombopoietic growth factors. Blood2007;109(11):4607‐16. ">Kuter 2007</a>). </p> <section id="CD009883-sec-0026"> <h4 class="title">Romiplostim</h4> <p>Romiplostim (synonym: AMG 53) is a thrombopoietin peptide mimetic that stimulates the megakaryocytopoiesis and generates increases in platelet counts by binding to the human thrombopoietin receptor (<a href="./references#CD009883-bbs2-0044" title="KuterDJ . Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annual Review of Medicine2009;60:193‐206. ">Kuter 2009</a>; <a href="./references#CD009883-bbs2-0061" title="StasiR , BosworthJ , RhodesE , ShannonMS , WillisF , Gordon‐SmithEC . Thrombopoietic agents. Blood2010;24(4‐5):179‐90. ">Stasi 2010</a>). Romiplostim is available as a lyophilised, powdery agent and is usually dissolvable in sterile water. It is syringed subcutaneously once a week at doses of 1 μg/kg to 10 μg/kg (<a href="./references#CD009883-bbs2-0040" title="KantarjianH , FenauxP , SekeresMA , BeckerPS , BoruchovA , BowenD , et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology2009;28(3):437‐44. ">Kantarjian 2009</a>; <a href="./references#CD009883-bbs2-0058" title="SekeresMA , KantarjianH , FenauxP , BeckerP , BoruchovA , Guerci‐BreslerA , et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer2011;117(5):992‐1000. ">Sekeres 2011a</a>). Single intravenous or subcutaneous injections in healthy people showed a dose‐responsive platelet production with an apparently linear relationship between platelet response and dose and a peak platelet count on days 12 to 16 without clinically significant adverse events (<a href="./references#CD009883-bbs2-0065" title="WangB , NicholJL , SullivanJT . Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clinical Pharmacology and Therapeutics2004;76(6):628‐38. ">Wang 2004</a>). </p> <p>Small non‐randomised trials examining the administration of romiplostim in thrombocytopenic patients with lower‐risk MDS have shown platelet responses (defined as eight consecutive weeks independent of platelet transfusions) in 46% to 57% of participants (<a href="./references#CD009883-bbs2-0040" title="KantarjianH , FenauxP , SekeresMA , BeckerPS , BoruchovA , BowenD , et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology2009;28(3):437‐44. ">Kantarjian 2009</a>; <a href="./references#CD009883-bbs2-0058" title="SekeresMA , KantarjianH , FenauxP , BeckerP , BoruchovA , Guerci‐BreslerA , et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer2011;117(5):992‐1000. ">Sekeres 2011a</a>). However, treatment‐related serious adverse events such as osteonecrosis, febrile neutropenia, thrombocytopenia and blast cell count increase were reported in five of 44 patients (11%) (<a href="./references#CD009883-bbs2-0040" title="KantarjianH , FenauxP , SekeresMA , BeckerPS , BoruchovA , BowenD , et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology2009;28(3):437‐44. ">Kantarjian 2009</a>). Furthermore, the European Medicines Agency recommended the use of romiplostim for the treatment of patients with MDS only in clinical trials, because cases of transient increases in blast cell counts were observed and cases of MDS disease progression to AML were reported (<a href="./references#CD009883-bbs2-0024" title="European Medicines Agency. Product information: Nplate. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000942/WC500039537.pdf (accessed 10 April 2012). ">EMEA 2011</a>). In addition, thromboembolic complications (i.e. portal vein thrombosis) have been reported in patients with chronic liver disease receiving romiplostim (<a href="./references#CD009883-bbs2-0015" title="HarperSE . Important information concerning updates to the US Nplate® (romiplostim). Prescribing Information, 2011. http://www.amgen.com/pdfs/products/NPlate‐DHCP‐2011‐07‐27.pdf.pdf (accessed 10 April 2012). ">AMGEN 2011</a>). </p> </section> <section id="CD009883-sec-0027"> <h4 class="title">Eltrombopag</h4> <p>Eltrombopag, a non‐peptide mimetic, also activates the thrombopoietin receptor by binding to it (<a href="./references#CD009883-bbs2-0043" title="KuterDJ . New thrombopoietic growth factors. Blood2007;109(11):4607‐16. ">Kuter 2007</a>; <a href="./references#CD009883-bbs2-0061" title="StasiR , BosworthJ , RhodesE , ShannonMS , WillisF , Gordon‐SmithEC . Thrombopoietic agents. Blood2010;24(4‐5):179‐90. ">Stasi 2010</a>). It is available as an orally administered drug, available as 25 mg, 50 mg or 75 mg tablets and should be taken daily and continuously on an empty stomach (<a href="./references#CD009883-bbs2-0043" title="KuterDJ . New thrombopoietic growth factors. Blood2007;109(11):4607‐16. ">Kuter 2007</a>; <a href="./references#CD009883-bbs2-0061" title="StasiR , BosworthJ , RhodesE , ShannonMS , WillisF , Gordon‐SmithEC . Thrombopoietic agents. Blood2010;24(4‐5):179‐90. ">Stasi 2010</a>). In healthy volunteers receiving eltrombopag for 10 days at doses of 5 mg, 10 mg, 25 mg, 30 mg, 50 mg and 75 mg platelet counts increased in a dose‐dependent manner. There were no differences in the incidence or severity of adverse events between eltrombopag and placebo (<a href="./references#CD009883-bbs2-0037" title="JenkinsJM , WilliamsD , DengY , UhlJ , KitchenV , CollinsD , et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood2007;109(11):4739‐41. ">Jenkins 2007</a>). </p> <p>So far, the effects of eltrombopag have only been researched on bone marrow mononuclear cells from patients with MDS and AML, healthy participants or laboratory animals in preclinical or phase I studies (<a href="./references#CD009883-bbs2-0037" title="JenkinsJM , WilliamsD , DengY , UhlJ , KitchenV , CollinsD , et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood2007;109(11):4739‐41. ">Jenkins 2007</a>). Ex vivo trials show that eltrombopag increases megakaryocytopoiesis in bone marrow mononuclear cells and does not influence the proliferation of malignant blasts. Adverse effects like headache, abdominal pain, sore throat and tiredness were not dose‐related and did not differ among treatment groups (<a href="./references#CD009883-bbs2-0037" title="JenkinsJM , WilliamsD , DengY , UhlJ , KitchenV , CollinsD , et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood2007;109(11):4739‐41. ">Jenkins 2007</a>; <a href="./references#CD009883-bbs2-0066" title="WillB , KawaharaM , LucianoJP , BrunsI , ParekhS , Erickson‐MillerC L , et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood2009;114(18):3899‐908. ">Will 2009</a>). </p> </section> <section id="CD009883-sec-0028"> <h4 class="title">Romiplostim and eltrombopag, experiences from their use in chronic idiopathic thrombocytopenic purpura (ITP) </h4> <p>Thrombopoietin mimetics (i.e. romiplostim and eltrombopag) have been approved for clinical use by the US Food and Drug Administration (FDA) for the treatment of chronic idiopathic thrombocytopenic purpura (ITP) (<a href="./references#CD009883-bbs2-0036" title="IkedaY , MiyakawaY . Development of thrombopoietin receptor agonists for clinical use. Journal of Thrombosis and Haemostasis2009;7(Suppl 1):239‐44. ">Ikeda 2009</a>). A Cochrane review investigating the use of romiplostim and eltrombopag for chronic ITP was published in 2011 by Zeng and colleagues (<a href="./references#CD009883-bbs2-0067" title="ZengY , DuanX , XuJ , NiX . TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD008235] ">Zeng 2011</a>). It included six trials with 808 patients (five studies compared thrombopoietin mimetics with placebo). Overall survival (OS) was not studied by these randomised controlled trials and despite significantly increased platelet response, there was no evidence to demonstrate that thrombopoietin mimetics compared to placebo or standard care improved significant bleeding events in chronic ITP. In summary, there is currently no evidence that supports the efficiency of these substances compared to placebo or other treatment options in patients with chronic ITP (<a href="./references#CD009883-bbs2-0067" title="ZengY , DuanX , XuJ , NiX . TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD008235] ">Zeng 2011</a>). </p> </section> </section> <section id="CD009883-sec-0029"> <h3 class="title" id="CD009883-sec-0029">Why it is important to do this review</h3> <p>Thrombocytopenia is a common clinical problem in patients with MDS and alternative treatment options to platelet transfusion are limited. Thrombopoietin mimetics (i.e. romiplostim and eltrombopag) currently, are the focus of clinical research (e.g. <a href="./references#CD009883-bbs2-0030" title="GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood. Washington (DC): American Society of Hematology, 2009:1769. ">Greenberg 2009</a>; <a href="./references#CD009883-bbs2-0041" title="KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010a</a>; <a href="./references#CD009883-bbs2-0047" title="LyonsRM , LarsonRA , KosmoMA , GandhiS , LiuD , ChernoffM , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. Washington (DC): American Society of Hematology, 2009:1770. ">Lyons 2009)</a>. They have been tested in MDS patients with thrombocytopenia and might be an effective treatment option for MDS patients (<a href="./references#CD009883-bbs2-0037" title="JenkinsJM , WilliamsD , DengY , UhlJ , KitchenV , CollinsD , et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood2007;109(11):4739‐41. ">Jenkins 2007</a>; <a href="./references#CD009883-bbs2-0040" title="KantarjianH , FenauxP , SekeresMA , BeckerPS , BoruchovA , BowenD , et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology2009;28(3):437‐44. ">Kantarjian 2009</a>; <a href="./references#CD009883-bbs2-0058" title="SekeresMA , KantarjianH , FenauxP , BeckerP , BoruchovA , Guerci‐BreslerA , et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer2011;117(5):992‐1000. ">Sekeres 2011a</a>). Nevertheless, the evidence of clinical efficacy of romiplostim and eltrombopag has not been assessed systematically. It is still uncertain whether thrombopoietin (TPO) mimetics can induce a meaningful clinical benefit in patients with MDS. Furthermore, it remains unclear whether they influence the increase of blast cells leading to premature progression to AML (<a href="./references#CD009883-bbs2-0024" title="European Medicines Agency. Product information: Nplate. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000942/WC500039537.pdf (accessed 10 April 2012). ">EMEA 2011</a>; <a href="./references#CD009883-bbs2-0040" title="KantarjianH , FenauxP , SekeresMA , BeckerPS , BoruchovA , BowenD , et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology2009;28(3):437‐44. ">Kantarjian 2009</a>). </p> <p>As far as we know at this stage one systematic review has been published, investigating safety and efficacy of thrombopoietin‐receptor (TPO‐R) agonists in MDS patients (<a href="./references#CD009883-bbs2-0055" title="PricaA , SholzbergM , BucksteinR . Safety and efficacy of thrombopoietin‐receptor agonsits in myelodysplastic syndromes: a systematic review and meta‐analysis of randomized controlled trials. British Journal of Haematology2014;167:626‐38. ">Prica 2014</a>). We are aiming to obtain more evidence regarding the clinical benefit (overall survival (OS), progression‐free survival (PFS), quality of life) and the therapy‐related risks (treatment‐related mortality, adverse events), by systematically analysing the reliability and validity of the data and by considering only randomised controlled trials for our review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009883-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009883-sec-0030"></div> <p>To evaluate the efficacy and safety of thrombopoietin (TPO) mimetics for patients with myelodysplastic syndromes (MDS). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009883-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009883-sec-0031"></div> <section id="CD009883-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009883-sec-0033"> <h4 class="title">Types of studies</h4> <p>We considered only randomised controlled trials as primary studies in this review and meta‐analysis. We included both full‐text and abstract publications. Randomisation is the best way to prevent systematic differences between baseline characteristics of participants between the two relevant intervention groups in terms of both known and unknown (or unmeasured) confounders (<a href="./references#CD009883-bbs2-0053" title="O'ConnorD , GreenS , Higgins JPT(editors) . Chapter 5: Defining the review question and developing criteria for including studies. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. .. ">O'Connor 2011</a>). We did not include cross‐over studies or quasi‐randomised trials. </p> </section> <section id="CD009883-sec-0034"> <h4 class="title">Types of participants</h4> <p>Participants had to be diagnosed with MDS. We included studies concerning all risk groups, without gender, age or ethnicity restrictions. If trials consisted of patients with different haematological malignancies, we only used data from the MDS subgroup. If subgroup data for MDS patients were not provided after contacting the author of the trial, we excluded the trial if less than 80% of patients had MDS. </p> </section> <section id="CD009883-sec-0035"> <h4 class="title">Types of interventions</h4> <p>We considered the following interventions:</p> <p> <ul id="CD009883-list-0002"> <li> <p>Experimental intervention: Thrombopoietin (TPO) mimetics</p> </li> </ul> <ul id="CD009883-list-0003"> <li> <p>Comparator intervention:</p> <ul id="CD009883-list-0004"> <li> <p>Placebo or no treatment</p> </li> <li> <p>Another TPO mimetic</p> </li> </ul> </li> </ul> </p> <p>We considered the following comparisons:</p> <p> <ul id="CD009883-list-0005"> <li> <p>TPO mimetic versus placebo or no treatment in MDS patients with thrombocytopenia</p> </li> <li> <p>TPO mimetic 1 versus TPO mimetic 2 in MDS patients with thrombocytopenia</p> </li> <li> <p>TPO mimetic versus placebo or no treatment in patients with MDS (thrombocytopenia is not described as an inclusion criteria of the study) </p> </li> <li> <p>TPO mimetic 1 versus TPO mimetic 2 in patients with MDS (thrombocytopenia is not described as an inclusion criteria of the study) </p> </li> </ul> </p> <p>We included trials comparing different dosages or time schedules of TPO mimetics.</p> <p>We evaluated only the first comparison as we identified only trials randomising thrombocytopenic patients to TPO mimetics or placebo. </p> <p>Additional chemotherapeutic treatment had to be equal in both arms except for the use of TPO mimetics. </p> </section> <section id="CD009883-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD009883-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009883-list-0006"> <li> <p>Overall survival (OS), defined as the time interval from random treatment assignment/entry into the study to death from any cause or to last follow‐up. </p> </li> <li> <p>Mortality during study</p> </li> </ul> </p> </section> <section id="CD009883-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p>We assessed the following secondary outcomes for all considered comparisons.</p> <p> <ul id="CD009883-list-0007"> <li> <p>Transformation to acute myeloid leukaemia (AML)</p> </li> <li> <p>Incidence of minor bleedings (analysed as incidence of bleeding events)</p> </li> <li> <p>Incidence of major bleedings (analysed as incidence of bleeding events)</p> </li> <li> <p>Transfusion requirement</p> </li> <li> <p>Health‐related quality of life was summarised, if available and measured with reliable and valid instruments. In the case that different questionnaires were used, we reviewed the concept of measurement of these instruments to compare, and if possible meta‐analyse, their content </p> </li> <li> <p>Adverse events (i.e. all adverse events of World Health Organization (WHO) grade III or IV; serious adverse events) </p> </li> <li> <p>Tumour control outcomes such as time to progression (e.g. progression‐free survival (PFS) (defined as time from randomisation to first evidence of progressive disease or death), or similar outcomes) </p> </li> </ul> </p> <p>We assessed the following secondary outcome only in trials that included thrombocytopenic patients with MDS. </p> <p> <ul id="CD009883-list-0008"> <li> <p>Platelet responses (we aimed to extract the increase of thrombocytes by at least 30,000/mm<sup>3</sup> or transfusion independence) </p> </li> </ul> </p> <p>We would have assessed the following secondary outcomes in trials that included patients with MDS (thrombocytopenia was not described as an inclusion criteria of the study), but did not identify any of these trials. </p> <p> <ul id="CD009883-list-0009"> <li> <p>Incidence of thrombocytopenia</p> </li> <li> <p>Duration of thrombocytopenia</p> </li> </ul> </p> </section> </section> </section> <section id="CD009883-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009883-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We adapted search strategies from those suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009883-bbs2-0045" title="LefebvreC , ManheimerE , Glanville J (authors) on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). No language restriction was applied to reduce the language bias. </p> <p>We searched the following databases of medical literature and started the search in 2000, as the intervention of interest (thrombopoietin mimetics) was mentioned the first time in 2000, in a trial in dogs (<a href="./references#CD009883-bbs2-0018" title="CaseBC , HauckML , YeagerRL , SimkinsAH , deSerresM , SchmithVD , et al. The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large‐animal model of chemotherapy‐induced thrombocytopenia. Stem Cells (Dayton, Ohio)2000;18(5):360‐5. [PUBMED: 11007920] ">Case 2000</a>): </p> <p> <ul id="CD009883-list-0010"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Library 2017, Issue 7 (<a href="./appendices#CD009883-sec-0091">Appendix 1</a>). </p> </li> <li> <p>MEDLINE (2000 to 01 August 2017) (<a href="./appendices#CD009883-sec-0093">Appendix 2</a>) </p> </li> </ul> </p> </section> <section id="CD009883-sec-0041"> <h4 class="title">Searching other resources</h4> <p>We searched the following conference proceedings from January 2000 to May 2017, if they were not included in CENTRAL. </p> <p> <ul id="CD009883-list-0011"> <li> <p>American Society of Hematology (ASH)</p> </li> <li> <p>American Society of Clinical Oncology (ASCO)</p> </li> <li> <p>European Hematology Association (EHA)</p> </li> <li> <p>European Society of Medical Oncology (ESMO)</p> </li> </ul> </p> <p>We electronically searched in the database of ongoing trials up to 05 May 2017.</p> <p> <ul id="CD009883-list-0012"> <li> <p>ISRCTN: http://www.isrctn.com</p> </li> <li> <p>EU clinical trials register: https://www.clinicaltrialsregister.eu/ctr‐search/search</p> </li> <li> <p>Clinicaltrials.gov: https://clinicaltrials.gov/</p> </li> </ul> </p> <p>In addition, we looked for studies in reference lists of relevant publications and at the European Group for Bone and Marrow Transplantation (available at: <a href="http://www.ebmt.org/" target="_blank">http://www.ebmt.org/</a>). </p> </section> </section> <section id="CD009883-sec-0042"> <h3 class="title" id="CD009883-sec-0042">Data collection and analysis</h3> <section id="CD009883-sec-0043"> <h4 class="title">Selection of studies</h4> <p>After the first review of all titles and abstracts of the identified studies from the above sources, two review authors independently rejected all studies that were clearly ineligible. We assessed selected studies by using an eligibility form regarding study design and compliance with inclusion criteria. The forms contained the following questions. </p> <p> <ul id="CD009883-list-0013"> <li> <p>Was the study described as randomised?</p> </li> <li> <p>Were the participants previously untreated?</p> </li> <li> <p>Were the patients diagnosed with MDS?</p> </li> <li> <p>Were the patients in the intervention group treated with TPO mimetics?</p> </li> <li> <p>Were the patients in the control group treated with placebo or no treatment or with a TPO mimetic? </p> </li> </ul> </p> <p>In case of doubt we included full‐text analysis and discussed eligibility with both review authors to finalise a decision (preferably including studies rather than losing relevant data). According to PRISMA we used a flow diagram to show numbers of identified records, excluded articles and included studies (<a href="#CD009883-fig-0001">Figure 1</a>) (<a href="./references#CD009883-bbs2-0050" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. ">Moher 2009</a>). </p> <div class="figure" id="CD009883-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009883-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009883-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (HD, NS) independently extracted data according to Chapter Seven of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009883-bbs2-0034" title="HigginsJPT , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>) by using a standardised data extraction form containing the following items. </p> <p> <ul id="CD009883-list-0014"> <li> <p>General information: Author, title, source, publication date, country, language, duplicate publications. </p> </li> <li> <p>Quality assessments: Sequence generation, allocation concealment, blinding (participants personnel outcome assessors), incomplete outcome data, selective outcome reporting, other sources of bias. </p> </li> <li> <p>Study characteristics: Trial design, aims, setting and dates, source of participants, inclusion/exclusion criteria, comparability of groups, subgroup analysis, statistical methods, power calculations, treatment cross‐overs, compliance with assigned treatment, length of follow‐up, time point of randomisation. </p> </li> <li> <p>Participant characteristics: Age; gender; number of participants recruited, allocated, evaluated; participants lost to follow‐up; stage of disease; type of International Prognostic Scoring System (IPSS); type of MDS. </p> </li> <li> <p>Interventions: TPO mimetics (treatment and control arm), best supportive care (treatment and control arm). </p> </li> <li> <p>Outcomes: OS, mortality, transformation to AML, transfusion requirements, incidence of minor bleedings, incidence of major bleedings, adverse events (i.e. all adverse events of WHO grade III or IV; serious adverse events), health‐related quality of life, platelet responses, tumour control outcomes such as time to progression (e.g. progression‐free survival, event‐free survival or disease‐free survival), incidence of thrombocytopenia, duration of thrombocytopenia. </p> </li> </ul> </p> </section> <section id="CD009883-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>To assess the methodological quality and the risk of bias we used a questionnaire according to the recommendations in Chapter Eight of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for the following criteria (<a href="./references#CD009883-bbs2-0035" title="HigginsJPT , AltmanDG , Sterne JAC (editors) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011c</a>). </p> <p> <ul id="CD009883-list-0015"> <li> <p>Sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding (participants, personnel, outcome assessors)</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other sources of bias</p> </li> </ul> </p> <p>The judgement of the review authors involved an answer for each criterion, based on a three‐point scale (low risk of bias, high risk of bias or unclear) and a summary description. </p> </section> <section id="CD009883-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes we calculated risk ratios (RR) with 95% confidence intervals (CIs) for each trial. We planned to calculate continuous outcomes as standardised mean difference (SMD), but no trial reported specific outcomes. For time‐to‐event outcomes we extracted the hazard ratio (HR) from published data according to <a href="./references#CD009883-bbs2-0054" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a> and <a href="./references#CD009883-bbs2-0063" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>. </p> </section> <section id="CD009883-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>As suggested in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009883-bbs2-0033" title="HigginsJPT , DeeksJJ , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>), there were many potential sources of missing data that had to be taken into account: at study level, at outcome level, at summary data level, at individual level and at study‐level characteristics (e.g. for subgroups analysis). It was important to differentiate between "missing at random" and "not missing at random". </p> <p>If data were assumed to be missing at random, we analysed only the available data (i.e. ignoring the missing data). </p> <p>In the case data were assumed not to be missing at random, we imputed the missing data with replacement values, and treated these as if they were observed (e.g. last observation carried forward, imputing an assumed outcome such as assuming all were poor outcomes, imputing the mean, imputing based on predicted values from a regression analysis). </p> </section> <section id="CD009883-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of treatment effects between trials by using a Chi<sup>2</sup> test with a significance level at P &lt; 0.1. We used the I<sup>2</sup> statistic to quantify possible heterogeneity (30% &lt; I<sup>2</sup> &lt; 75%: moderate heterogeneity, 75% &lt; I<sup>2</sup>: considerable heterogeneity) (<a href="./references#CD009883-bbs2-0021" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> <p>We accomplished subgroups by tests for interaction.</p> </section> <section id="CD009883-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>As we did not conduct meta‐analyses with at least 10 trials, we were not able to explore the potential publication bias by generating a funnel plot. In future updates we will test potential publication bias with a linear regression test and considering P &lt; 0.1 as significant for this test (<a href="./references#CD009883-bbs2-0062" title="SterneJAC , EggerM , Moher D (editors) on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Sterne 2011</a>). </p> </section> <section id="CD009883-sec-0050"> <h4 class="title">Data synthesis</h4> <p>We performed analyses according to the recommendations of Chapter Nine of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009883-bbs2-0021" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). We used aggregated data for analysis. For statistical analysis, we entered data into the Cochrane statistical package Review Manager (RevMan) 5. One review author entered data into the software and a second review author checked it for accuracy. As the trials were heterogenous in terms of clinical characteristics (e.g. concomitant medication), we performed meta‐analyses using a random‐effects model (e.g. the generic inverse variance method for survival data outcomes and Mantel‐Haenszel method for dichotomous data outcomes). We used the fixed‐effect model in terms of sensitivity analyses. </p> <p>We created a 'Summary of findings' table on absolute risks with the help of GRADE. We summarised the evidence of mortality during study, transformation to AML, incidence of bleeding events, transfusion requirement, health‐related quality of life, all adverse events, and serious adverse events in <a href="./full#CD009883-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD009883-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We assessed heterogeneity of treatment effects between trials by using a Chi² test with a significance level at P &lt; 0.1. We used the I² statistic to quantify possible heterogeneity. We performed subgroup analyses on the following characteristics. </p> <p> <ul id="CD009883-list-0016"> <li> <p>Different types of TPO mimetics</p> </li> <li> <p>Different types of additional agents (e.g. no other additional agent versus other chemotherapeutics) </p> </li> <li> <p>Different types of MDS risk groups</p> </li> </ul> </p> </section> <section id="CD009883-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses on the following characteristics. :</p> <p> <ul id="CD009883-list-0017"> <li> <p>Fixed‐effect modelling versus random‐effects modelling</p> </li> <li> <p>We performed sensitivity analysis regarding full‐text publications versus abstract only publication </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009883-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009883-sec-0053"></div> <section id="CD009883-sec-0054"> <h3 class="title">Description of studies</h3> <p>For study details please see: <a href="#CD009883-sec-0056">Included studies</a>; <a href="#CD009883-sec-0057">Excluded studies</a> </p> <section id="CD009883-sec-0055"> <h4 class="title">Results of the search</h4> <p>We identified 679 potentially relevant references through database searches and handsearching. Of these, we excluded 653 at the initial stage of screening because they did not fulfil our predefined inclusion criteria. We checked the remaining 26 publications for detailed evaluation. Of these, we excluded nine publications. Finally, we included six eligible trials (in 17 publications) with 812 patients in this review. A total of 746 patients entered the meta‐analysis, as 66 patients in the <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> trial where analysed with AML and therefore excluded in this review. </p> <p>The overall number of trials screened, identified, selected, excluded and included was documented with reasons according to PRISMA flow diagram (see <a href="#CD009883-fig-0001">Figure 1</a>). </p> </section> <section id="CD009883-sec-0056"> <h4 class="title">Included studies</h4> <p>We included six trials (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>; <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>) in this review. We extracted data from full‐text publications for five trials (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>), one trial was published as an abstract (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>). All studies were published in English. We included a total of 746 MDS patients who fulfilled our predefined criteria. </p> <p>Details of the methods, participants, interventions and outcome measures of individual studies are summarised in <a href="./references#CD009883-sec-0102" title="">Characteristics of included studies</a>. </p> <p><b>Design</b> </p> <p>All studies were reported to be randomised, double‐blind and placebo‐controlled trials. Of all the included trials, four trials were two‐armed randomised controlled trials (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>; <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>) and two trials were three‐armed randomised controlled trials (<a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). With the exception of <a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>, all trials were reported to be multicentre studies. </p> <p><b>Sample size</b> </p> <p>Sample sizes ranged from 29 patients (<a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>) to 356 patients (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>). </p> <p><b>Location</b> </p> <p>Three included trials were carried out in the USA (<a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>) and the other three trials were performed by an international study group (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>; <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>). </p> <p><b>Participants</b> </p> <p>We included a total of 746 male and female patients. Of these, 236 patients were randomised to romiplostim, 227 patients were randomised to eltrombopag and 283 patients were randomised to placebo. For all trials, patients from 18 years of age and older were enrolled. The median age of participants was 68 years (range 52 to 84) (<a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>), 70 years (range 24 to 89) (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>), 70 years (range 61 to 77) (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>), 71 (range 56 to 86) (<a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>), 71 years (range 40 to 91) in the placebo group and 73 years (range 29 to 88) in the eltrombopag group (<a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>) and 74 years (range 39 to 90) (<a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). Four trials included low‐ and intermediate‐1 risk MDS patients (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>), one trial included intermediate‐1, intermediate‐2 and high‐risk MDS patients (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>), and one trial included advanced MDS and AML patients (<a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>). However, from this trial only patients diagnosed with MDS were included in the current review. </p> <p><b>Interventions</b> </p> <p>Four trials analysed the thrombopoietin (TPO) mimetic romiplostim (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). In two trials patients received the TPO mimetic eltrombopag (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>). In two trials a dose of 750 µg romiplostim was evaluated versus placebo (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>). Two trials assessed two different dose schedules (750 µg or 500 µg) of romiplostim and were analysed as three‐armed trials with the different doses included as one arm versus placebo (<a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). In four trials, patients concurrently received the hypomethylating agents azacitidine (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>) or decitabine (<a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>) or the immunomodulatory drug lenalidomide (<a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). The duration of studies ranged from four 28‐day cycles (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>), six months (<a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>) to &gt; 58 weeks (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>). No trial drew a comparison between two different kinds of TPO mimetics. </p> <p><b>Primary outcome measure</b> </p> <p>We elaborated overall survival (OS) in two trials (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>), however as <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> did not report 95% confidence intervals (CIs), data could not be meta‐analysed. </p> <p>Due to absence of applicable data referring to OS we used "mortality during study" as a new primary outcome. This outcome was reported by all trials. </p> <p><b>Secondary outcome measures</b> </p> <p>Transformation to AML was reported in five studies (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). Data with regard to minor and major bleeding events were summarised as incidence of bleeding events and reported by five trials as follows: all bleeding events (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>, <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>) and grade &gt;= three haemorrhages (<a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>). Four trials (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>) assessed transfusion requirement. Progression‐free survival (PFS) was assessed by <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> as median PFS in weeks. <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a> reported PFS as AML‐free survival. Five trials reported all adverse events (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>); &gt;= grade 3 adverse events were reported by <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>, <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>, <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> and <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>. Four trials published data regarding serious adverse events (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). As platelet response was only assessed in trials that included thrombocytopenic patients with MDS, only <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> provided information regarding this outcome. No trial mentioned duration of thrombocytopenia or health‐related quality of life. </p> <p>Due to insufficient data or variable definition of the outcome, we only included mortality during the study, transformation to AML, transfusion requirement, incidence of bleeding events, all adverse events, adverse events &gt;= grade 3, and serious adverse events in the meta‐analysis. </p> <p><b>Conflict of interest</b> </p> <p>All trials disclosed their conflict of interest and were supported by the pharmaceutical industry as follows. </p> <p> <ul id="CD009883-list-0018"> <li> <p><a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>: All authors were either employee, consultant, participant in speakers´ bureau or received funding or honoraria from <i>GlaxoSmithKline, Celgene Corporation, Janssen‐Cilag, Novartis, Astex, TEVA Pharmaceutical Industries, Pfizer or Roche</i> </p> </li> <li> <p><a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>: All authors were either employee, consultant, equity owner, advisory committee member or received funding or honoraria from <i>Amgen, Alexion, Bristol Myers Squibb, GlaxoSmithKline, Celgene, Roche, Janssen Cilag</i> or <i>Celgene Corp.</i> </p> </li> <li> <p><a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>: five of eight authors were either employee, spokesman, consultant, equity owner, advisory committee member or received funding from <i>Novartis, Eisai, Genentech, Celgene</i> or <i>Amgen Inc..</i> </p> </li> <li> <p><a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>: All authors were either employee, consultant or advisor of <i>Amgen.</i> </p> </li> <li> <p><a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>: 10 of 11 authors were either advisory board member, employee, consultant or received funding or honoraria from <i>Amgen, GlaxoSmithKline, Novartis</i> or were participants in speakers´ bureau for <i>Astellas Pharma, Bayer, Boehringer Ingelheim, Bristol‐Myers Squibb, Covidien, GlaxoSmithKline, Hospira, Leo Pharma</i> and<i>Novartis.</i> </p> </li> <li> <p><a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>: All authors were either employee, spokesman, consultant, equity owner or received funding or honoraria from <i>GlaxoSmithKline, Johnson&amp;Johnson, Celgene</i> or <i>Amgen Inc.</i> </p> </li> </ul> </p> </section> <section id="CD009883-sec-0057"> <h4 class="title">Excluded studies</h4> <p>A total of six studies (eight articles) were excluded after detailed evaluation of full‐text publications. The main reasons for exclusion were: </p> <p> <ul id="CD009883-list-0019"> <li> <p>one review</p> </li> <li> <p>six publications of non‐randomised controlled trials</p> </li> <li> <p>one study included patients with different haematological malignancies; data from the MDS subgroup were not reported </p> </li> </ul> </p> <p>For information on excluded trials see <a href="./references#CD009883-sec-0103" title="">Characteristics of excluded studies</a>, where reasons for the exclusion are listed. </p> <section id="CD009883-sec-0058"> <h5 class="title">Ongoing studies (one already completed awaiting final results)</h5> <p>Currently there are two ongoing trials.</p> <p><a href="./references#CD009883-bbs2-0013" title="A three‐part study of eltrombopag in thrombocytopenic patients with myelodysplastic syndromes or acute myeloid leukaemia (part 1: open‐label, part 2: randomised, double‐blind, part 3: extension). Ongoing studySeptember 2011. ">NCT01440374</a> is a three‐part (part 1: open‐label, part 2: randomised, double‐blind, part 3: extension) worldwide, multicentre study, also sponsored by <i>GlaxoSmithKline</i>. It started in September 2011 and finally included 162 patients. Participants with MDS or AML who have thrombocytopenia due to bone marrow insufficiency from their underlying disease or prior chemotherapy have been enrolled. In part 2 of this study; MDS patients were randomised to receive eltrombopag in comparison to placebo. Study completion date was September 2015, but no final results for MDS patients have been published, only data for AML and MDS patients together. </p> <p><a href="./references#CD009883-bbs2-0014" title="OlivaE , LatagliataR , SantiniV , PalumboG , PoloniA , CortelezziA , et al. Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and int‐1 risk MDS: Preliminary results of a prospective, randomized, single‐blind placebo‐controlled trial. Haematologica. 2012. OlivaEN , AlatiC , SantiniV , PoloniA , MolteniA , NiscolaP , et al. Eltrombopag versus placebo for low‐risk myelodysplastic syndromes with thrombocytopenia (EQoL‐MDS): phase 1 results of a single‐blind, randomised, controlled, phase 2 superiority trial. Lancet Haematology2017;4(3):e127‐36. [PUBMED: 28162984] OlivaEN , SantiniV , ZiniV , PalumboGA , PoloniA , CortelezziA , et al. Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and int‐1 IPSS risk myelodysplastic syndromes: Interim analysis of a prospective, randomized, single‐blind, placebo‐controlled trial (EQoL‐MDS) [abstract no. 923]. Blood. 2012. ">Oliva 2017</a> is a phase II, multicentre, prospective, placebo‐controlled single‐blind study. An interim report based on data of 90 patients has been reported, 174 patients will be included in this trial. Eligible participants receive eltrombopag in comparison to placebo; study completion is planned for 2019. </p> <p>Detailed information regarding these trials is summarised under <a href="./references#CD009883-sec-0104" title="">Characteristics of ongoing studies</a>. </p> </section> </section> </section> <section id="CD009883-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall the potential risk of bias of included trials is high. The judgement is graphically summarised in <a href="#CD009883-fig-0002">Figure 2</a> and <a href="#CD009883-fig-0003">Figure 3</a>. For more information see risk of bias table of included trials in <a href="./references#CD009883-sec-0102" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD009883-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009883-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009883-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009883-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009883-sec-0060"> <h4 class="title">Allocation</h4> <p>Four trials (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>) reported allocation concealment using an interactive voice response system (IVRS) for randomisation. We supposed that <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a> also used IVRS for randomisation as it is part A of the <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a> trial. We judged allocation concealment for these trials as low risk. As <a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a> provided insufficient data according allocation we judged this study to have an unclear risk. For all included trials sequence generation was judged to be low risk. </p> </section> <section id="CD009883-sec-0061"> <h4 class="title">Blinding</h4> <p>All trials reported to be double‐blind, but provided insufficient information regarding this item. Nevertheless, we judged the risk of performance bias for these trials as low risk as we assume it was adequate. </p> </section> <section id="CD009883-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>There was no suggestion of incomplete outcome data in all trials. Therefore we judged low risk for all trials. </p> </section> <section id="CD009883-sec-0063"> <h4 class="title">Selective reporting</h4> <p>Study protocols were available for all trials. All of the studies' pre‐specified primary and secondary outcomes that are of interest in the review were reported by four trials (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>); we judged risk of selective reporting as low for these trials. <a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a> was judged as high risk for selective reporting as fewer outcomes than the protocol‐predefined outcomes have been published. We judged <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> to be high risk as only a subgroup analysis for MDS patients was published as an abstract publication (this may have influenced the outcome of transformation to AML). More importantly, there has been no full report of the total MDS population. </p> </section> <section id="CD009883-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>Due to small sample sizes and imbalances in baseline characteristics (e.g. mismatch within arms regarding severity of the MDS disease, enrolment of patients with diverging baseline platelet counts, no individually‐adjusted TPO‐mimetic doses to bring platelets into a target range), we judged high risk in three trials (<a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a> was discontinued earlier due to concerns regarding the potential for transient increases in blast cell counts and the risk for progression to or treatment for AML. Therefore, we also judged this trial to be at high risk. As the <a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a> trial was prematurely stopped, because outcomes crossed the predefined futility threshold and for safety reasons we also judged high risk of bias for this item. We did not identify other risk of bias for the <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> trial, therefore we judge as low risk of potential bias. </p> <p>All trials were funded by the pharmaceutical industry.</p> </section> </section> <section id="CD009883-sec-0065"> <h3 class="title" id="CD009883-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD009883-tbl-0001"><b>Summary of findings for the main comparison</b> Thrombopoietin mimetics compared to placebo for patients with myelodysplastic syndromes</a> </p> <p>We did not identify any trial evaluating one thrombopoietin (TPO) mimetic versus another. The following results are for the comparison of one TPO mimetic versus placebo or in addition to standard therapy compared to standard therapy only. All trials included thrombocytopenic patients, therefore all trials were analysed in one meta‐analysis. </p> <section id="CD009883-sec-0066"> <h4 class="title">Primary outcome: Overall survival (OS)</h4> <p>Data of overall survival (OS) were available from <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a> and <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> with a total of 282 (TPO mimetic/placebo: 185/97) patients. This outcome was defined as OS within a predefined period (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>) and as OS in weeks (<a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>). </p> <p>In <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>, OS was assessed during the 58‐week study period and included the time to follow‐up for participants who discontinued the study drug earlier. There was no evidence for a difference between treatment groups with 18% of romiplostim patients dying and 20.5% of placebo patients (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.48 to 1.56). </p> <p><a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> reported a median OS of 34 weeks for eltrombopag‐treated patients in comparison to 15.4 weeks for placebo‐treated. The HR was 0.70 without evidence for a difference (P = 0.38). As <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> did not provide 95% CI, data could not be meta‐analysed. </p> <p>Subgroup and sensitivity analysis were not performed, because the identified studies were not meta‐analysed. </p> </section> <section id="CD009883-sec-0067"> <h4 class="title">Primary outcome: Mortality during study</h4> <p>All trials released information regarding mortality during study with a total of 746 (TPO mimetic/placebo: 433/313) patients. </p> <p>With regards to mortality during study, there is little or no evidence for a difference in the pooled analysis (RR 0.97, 95% CI 0.73 to 1.27, P = 0.80; six trials, 746 patients; low‐quality evidence; <a href="./references#CD009883-fig-0007" title="">Analysis 1.1</a>; <a href="#CD009883-fig-0004">Figure 4</a>). The same is true for the subgroup analysis for different types of TPO mimetic, different types of additional agents and different types of MDS risk groups (<a href="./references#CD009883-fig-0009" title="">Analysis 1.3</a>; <a href="./references#CD009883-fig-0010" title="">Analysis 1.4</a>; <a href="./references#CD009883-fig-0011" title="">Analysis 1.5</a>). By comparing fixed‐effect modelling (FE) versus random‐effects modelling (RE) in the sensitivity analysis, there was also no evidence for a difference between both models (<a href="./references#CD009883-fig-0008" title="">Analysis 1.2</a>). </p> <div class="figure" id="CD009883-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.1 Mortality during study ‐ all." data-id="CD009883-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.1 Mortality during study ‐ all. </p> </div> </div> </div> <p>In the original analysis from June 2011, <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a> reported that 18% of patients in the romiplostim and 20.5% of patients in the placebo group died (HR 0.86, 95% CI 0.48 to 1.56). These data were used for the meta‐analysis on mortality during the study. The trial was discontinued early, due to a potentially increased risk of AML caused by romiplostim. We did not use the long‐term follow‐up data as the patients did not receive the study drug any longer during this period. </p> <p><a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a> documented the death of three patients. One death caused by neutropenic sepsis was considered to be related to the hypomethylating agent decitabine. <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a> mentioned two patients who died in the placebo group from fungal pneumonia and from endocarditis. <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> provided information regarding five eltrombopag‐treated and six placebo‐treated patients dying on therapy or &lt; 30 days from the last drug administration. There were 57 cases of death (32%) in the eltrombopag arm and 51 cases of death (29%) in the placebo arm in <a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>. Within 30 days after end of treatment, 33 events of death (19%) were reported in the eltrombopag group and 29 events of death (16%) were reported in the placebo group. More than 10% of all deaths were caused by diseases under study treatment and sepsis. In <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>, one patient in the 750 µg romiplostim group died of intestinal obstruction in the extension period without any relation to romiplostim treatment. </p> </section> <section id="CD009883-sec-0068"> <h4 class="title">Secondary outcome: Transformation to Acute myeloid leukaemia (AML)</h4> <p>Data regarding transformation to AML were available from five trials (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>) with a total of 390 (TPO mimetic/placebo: 254/136) patients. </p> <p>There was no evidence for a difference concerning transformation to AML (RR 1.02, 95% CI 0.59 to 1.77, P = 0.94; five trials, 372 patients; very low‐quality evidence; <a href="./references#CD009883-fig-0013" title="">Analysis 1.7</a>; <a href="#CD009883-fig-0005">Figure 5</a>). There was no evidence for subgroup differences in the analyses of different types of TPO mimetics, different types of additional agents and different types of MDS risk groups (<a href="./references#CD009883-fig-0015" title="">Analysis 1.9</a>; <a href="./references#CD009883-fig-0016" title="">Analysis 1.10</a>; <a href="./references#CD009883-fig-0017" title="">Analysis 1.11</a>). By comparing fixed‐effect modelling (FE) versus random‐effects modelling (RE) in the sensitivity analysis, we could not identify any relevant difference between both models (<a href="./references#CD009883-fig-0014" title="">Analysis 1.8</a>). </p> <div class="figure" id="CD009883-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.7 Transformation to AML ‐ all." data-id="CD009883-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.7 Transformation to AML ‐ all. </p> </div> </div> </div> <p>In 2011, <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a> detected a non‐statistically significant increased risk of transformation to AML with HR 2.51, (95% CI 0.55 to 11.47, P = 0.23). Due to concerns of premature AML progression, these results led to early withdrawal of the study. However, two romiplostim‐treated patients with increasing peripheral blast cell counts achieved treatment for AML without having a bone marrow puncture four weeks after discontinuation of romiplostim. These patients were counted as AML‐progressed patients. In addition, in both arms there were more patients with RAEB‐1/RAEB‐2 (refractory anaemia with excess blasts) among those developing AML. Long‐term follow‐up analyses regarding this issue from 2011 were well balanced for both arms (HR 1.15, 95% CI 0.47 to 2.85). Updated follow‐up results from 2012 again presented balanced numbers of AML‐progression for both arms (HR 1.14, 95% CI 0.49 to 2.62). Finally, five‐year long‐term follow‐up from December 2016 confirmed all previous follow‐up data (HR 1.06, 95% CI 0.48 to 2.33) with 20 (11.9%) patients developing AML in the romiplostim arm and 9 (11.0%) patients developing AML in the placebo arm. </p> </section> <section id="CD009883-sec-0069"> <h4 class="title">Secondary outcome: Incidence of bleeding events</h4> <p>We meta‐analysed data of all reporting trials with a total of 390 patients (TPO mimetic/placebo: 254/136). Analysable data with regard to bleeding events were reported by five trials as follows: all number of bleeding events (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>) and grade &gt;= 3 bleeding events (<a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>). </p> <p>Comparing these trials, treatment with TPO mimetics resulted in a statistically significant lower incidence of all bleeding events compared to placebo (RR 0.92, 95% CI 0.86 to 0.98, P = 0.02; <a href="./references#CD009883-fig-0018" title="">Analysis 1.12</a>; five trials, 390 patients; moderate‐quality evidence see <a href="#CD009883-fig-0006">Figure 6</a>). There was no evidence for a difference for the subgroup analyses of different types of TPO mimetics, different types of additional agents, different MDS risk groups and grade &gt;= grade 3 versus all bleeding events (<a href="./references#CD009883-fig-0020" title="">Analysis 1.14</a>; <a href="./references#CD009883-fig-0021" title="">Analysis 1.15</a>; <a href="./references#CD009883-fig-0022" title="">Analysis 1.16</a>; <a href="./references#CD009883-fig-0023" title="">Analysis 1.17</a>). Moreover, we could not identify any significant difference between fixed‐effect model and random‐effects model (<a href="./references#CD009883-fig-0019" title="">Analysis 1.13</a>). </p> <div class="figure" id="CD009883-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.12 Incidence of bleeding events ‐ all." data-id="CD009883-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.12 Incidence of bleeding events ‐ all. </p> </div> </div> </div> </section> <section id="CD009883-sec-0070"> <h4 class="title">Secondary outcome: Transfusion requirement</h4> <p>Four trials (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>) with a total of 358 (TPO/placebo: 236/122) patients provided informations regarding transfusion requirement. </p> <p>Regarding transfusion requirement, there was no evidence for a difference between patients treated with TPO mimetic or placebo (RR 0.83, 95% CI 0.66 to 1.05, P = 0.11; four trials, 358 patients; low‐quality evidence; <a href="./references#CD009883-fig-0024" title="">Analysis 1.18</a>). There was no evidence for a difference in the subgroup analysis of different types of additional agents (<a href="./references#CD009883-fig-0026" title="">Analysis 1.20</a>) and no relevant difference between fixed‐effect and random‐effects model (<a href="./references#CD009883-fig-0025" title="">Analysis 1.19</a>). </p> <p><a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a> reported a higher need of platelet transfusions in patients with intermediate‐2 risk (86%) in comparison to patients with low‐ or intermediate‐1 risk (38%) MDS. Unfortunately, due to missing data regarding different MDS risk groups, we had to we were unable to carry out this subgroup analysis. Subgroup analysis in terms of "different types of thrombopoietin mimetics" was also not performed, because the identified studies showed no differences or presented insufficient data regarding these study characteristics. </p> </section> <section id="CD009883-sec-0071"> <h4 class="title">Secondary outcome: Health‐related quality of life</h4> <p>No trial provided sufficient data to interpret health‐related quality of life.</p> </section> <section id="CD009883-sec-0072"> <h4 class="title">Secondary outcome: Duration of thrombocytopenia</h4> <p>None of the trials reported duration of thrombocytopenia.</p> </section> <section id="CD009883-sec-0073"> <h4 class="title">Secondary outcome: All adverse events</h4> <p>Five trials with a total of 390 (TPO mimetic/placebo: 254/136) patients reported total number of patients affected by adverse events (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). </p> <p>Concerning this outcome, there was no evidence for a difference (RR 1.01, 95% CI 0.96 to 1.07, P = 0.67; five trials, 390 patients; moderate‐quality evidence; <a href="./references#CD009883-fig-0027" title="">Analysis 1.21</a>). There was also no evidence for a difference in the subgroup analyses of different types of TPO mimetics, different types of additional agents and different MDS risk groups (<a href="./references#CD009883-fig-0029" title="">Analysis 1.23</a>; <a href="./references#CD009883-fig-0030" title="">Analysis 1.24</a>; <a href="./references#CD009883-fig-0031" title="">Analysis 1.25</a>) and in the sensitivity analysis (<a href="./references#CD009883-fig-0028" title="">Analysis 1.22</a>). </p> <p>All adverse events reported in this trial are presented in <a href="#CD009883-tbl-0002">Table 1</a>. </p> <div class="table" id="CD009883-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo = 83</p> <p>TPO mim. = 167</p> <p>(PBO / TPO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo = 14</p> <p>TPO mim. = 15</p> <p>(PBO / TPO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo = 13</p> <p>TPO mim. = 27</p> <p>(PBO / TPO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo = 14</p> <p>TPO mim. = 18</p> <p>(PBO / TPO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo = 9</p> <p>TPO mim. = 28</p> <p>(PBO / TPO)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 / 157 <sup>2)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 / 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 / 27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 / 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 / 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 1 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 2 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 3 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 / 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 / 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥<b>Grade 3 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 / 13 <sup>9)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 4 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 5 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 / 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 / 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 /13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peripheral oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Contusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 / 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash &amp; hypersensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 / 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain in extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IP‐related adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 14 <sup>6)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 / 67<sup>1)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 / 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 / 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 9 <sup>12)</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 / 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 / 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ Grade 3 bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haematoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Febrile neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myelofibrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>3)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythema nodosum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypokalemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IP‐related SAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 2 <sup>7)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cerebrovascular accident</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endocarditis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary artery thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1 <sup>4)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fungal pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutropenic sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deaths</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 / 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 1 <sup>5)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 0<sup>8)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1 <sup>10)</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE leading to withdrawal</b> </p> <p><b>or IP discontinuation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 3 <sup>11)</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Legend:<i><b>AE</b> </i> adverse event; <i><b>IP</b> </i> investigational product; <i><b>n. r.</b> </i> not reported </p> <p><sup>1)</sup>Serious AE related to romiplostim: 12 patients ( increased myeloblast count, colon cancer, deep vein thrombosis, extramedullary haemopoiesis, leukocytosis, myelofibrosis, pneumonia, pyrexia, splenic infarction, transient ischaemic attack, type 2 diabetes mellitus) </p> <p><sup>2)</sup>Adverse event in both study arms: Epistaxis, hematoma, petechiae </p> <p><sup>3)</sup>Two romiplostim‐treated patients had myelofibrosis. One patient had disease progression and was reported to have grade 3 bone marrow fibrosis on day 35 of treatment. This event was reported being related to romiplostim. The second patient had a history of myelofibrosis and progressed to grade 2 bone marrow fibrosis on day 71 and grade 3 bone marrow fibrosis on day 99 of treatment. None of these event were considered related to romiplostim treatment. </p> <p><sup>4)</sup>One patient (7%) in the romiplostim group; pulmonary artery thrombosis was reported as treatment‐related serious adverse event </p> <p><sup>5)</sup>Three deaths occurred during treatment period. None was considered related to treatment, although neutropenic sepsis was considered related to decitabine. No deaths occurred during extension period. One death was reported in the romiplostim group who died from cholecystitis ≥30 days after last dose of romiplostim </p> <p><sup>6)</sup>All treatment‐related adverse events were grade 1 or 2, except for grade 3 arthralgia in one patient in the romiplostim 500 µg group and one patient with grade 3 rash in the 750 µg group. </p> <p><sup>7)</sup>Three patients had treatment‐related serious adverse events, two in the placebo group ( myelofibrosis and erythema nodosum) and one patient with grade 3 rash in the romiplostim 750 µg group. </p> <p><sup>8)</sup>One patient died from fungal pneumonia and one from endocarditis. </p> <p><sup>9)</sup>The most common ≥ grade 3 AE in the eltrombopag vs PBO groups were: febrile neutropenia (6% / 29%), anaemia (11% / 14%), pneumonia (11% / 14%) and sepsis (11% / 14%). </p> <p><sup>10)</sup>One patient in the 750µg romiplostim group died during the extension period from intestinal obstruction, which was not considered related to romiplostim. </p> <p><sup>11)</sup>Adverse events leading to study withdrawal were pancytopenia, asthenia, and cerebrovascular accident in the placebo group; pancytopenia and rash in the romiplostim 500µg group; and thrombocytopenia in the 750µg group. Only cerebrovascular accident in the placebo group was considered related to IP. </p> <p><sup>12)</sup>Only two serious AE were considered related to treatment: Cerebrovascular accident in one patient in the placebo group and worsening thrombocytopenia in one patient in the romiplostim 500µg group. </p> </div> </div> </section> <section id="CD009883-sec-0074"> <h4 class="title">Secondary outcome: Adverse events &gt;= grade 3</h4> <p>Adverse events &gt;= grade 3 were reported by five trials (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>; <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>) with a total of 494 patients (TPO mimetic/placebo: 267/227). Four trials were meta‐analysed regarding this outcome (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). </p> <p>The analysis of adverse events &gt;= grade 3 showed no evidence for a difference (RR 0.98, 95% CI 0.74 to 1.31, P = 0.91;four trials, 138 patients; <a href="./references#CD009883-fig-0032" title="">Analysis 1.26</a>). All subgroup analyses and the sensitivity analysis confirmed this finding (<a href="./references#CD009883-fig-0034" title="">Analysis 1.28</a>; <a href="./references#CD009883-fig-0035" title="">Analysis 1.29</a>; <a href="./references#CD009883-fig-0036" title="">Analysis 1.30</a>; <a href="./references#CD009883-fig-0033" title="">Analysis 1.27</a>). </p> <p><a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a> reported 195 adverse events &gt;= grade 3 in the eltrombopag arm and 137 adverse events &gt;= grade 3 in the placebo arm. As in this trial the number of adverse event were counted, instead of the number of patients, this trial could not be added to the meta‐analysis. </p> </section> <section id="CD009883-sec-0075"> <h4 class="title">Secondary outcome: Serious adverse events</h4> <p>Four trials including 358 patients (thrombopoietin mimetic/placebo: 236/122) reported this outcome (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>; <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>). </p> <p>Regarding serious adverse events there was no evidence for a difference between arms (RR = 0.89, 95% CI 0.54 to 1.46, P = 0.64; four trial, 356 patients; very low‐quality evidence; <a href="./references#CD009883-fig-0037" title="">Analysis 1.31</a>). </p> <p>In the subgroup analysis of different types of additional agents <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>, the only trial solely treating with romiplostim monotherapy, showed a statistically significant advantage for the placebo arm (RR = 1.51, 95% CI 1.01 to 2.27, P = 0.04). <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>, substituting a combination therapy of romiplostim and the immunomodulatory drug lenalidomide, showed a statistically significant advantage for the TPO arm (RR 0.48, 95% CI 0.24 to 0.98, P = 0.04). The test for differences between subgroups for different types of additional agents was statistically significant (P = 0.010) (<a href="./references#CD009883-fig-0039" title="">Analysis 1.33</a>). However, due to the very low number of patients included in the <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a> trial, certainty in this effect estimate is very low. </p> </section> <section id="CD009883-sec-0076"> <h4 class="title">Secondary outcome: Progression‐free survival (PFS)start here</h4> <p>Two trials with a total of 282 patients (thrombopoietin mimetic/placebo: 185/97) reported this outcome. Progression‐free survival (PFS) was reported as AML‐free survival in two different ways: <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a> published data about patient numbers reaching this outcome. <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> defined this outcome as time span of weeks. Due to different outcome definitions this item did not undergo a meta‐analysis. </p> <p>At the time of study discontinuation in February 2011 <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a> reported similar rates of AML‐free survival between treatment arms (HR 0.86, 95% CI 0.49 to 1.51). 33 (19.8%) of the romiplostim‐treated patients and 19 (22.9%) of placebo‐treated patients had an AML‐free survival. However, two romiplostim‐treated patients with increasing peripheral blast cell counts achieved treatment for AML without having a bone marrow puncture four weeks after discontinuation of romiplostim. These patients were counted as AML‐progressed patients. In addition, in both arms there were more patients with RAEB‐1/RAEB‐2 among those developing AML. Follow‐up results in 2012 (data beyond 58 weeks) documented a HR of 1.11 (95% CI 0.72 to 1.70) with 66 (39.5%) of the romiplostim‐treated patients and 32 (38.6%) of placebo‐treated patients. In November 2013 updated follow‐up results confirmed these results (HR 1.14, 95% CI 0.49 to 2.62). Final five‐year long‐term follow‐up data from December 2016 again reinforced the non‐impact of romiplostim on PFS (HR 1.04, 95% CI 0.73 to 1.48). Due to missing data regarding the P value we were not able to make a statement regarding statistical significance. </p> <p><a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> presented a median PFS of 16.1 weeks for eltrombopag patients compared to 7.7 weeks for placebo patients with a HR of 0.61. With P = 0.1531 this result was not statistically significant. </p> <p>Subgroup and sensitivity analysis were not performed, because the identified studies were not meta‐analysed. </p> </section> <section id="CD009883-sec-0077"> <h4 class="title">Secondary outcome: Platelet response</h4> <p>As mentioned in <a href="#CD009883-sec-0031">Methods</a>, this outcome was only assessed in trials that included thrombocytopenic patients with MDS. Only one trial with a total of 32 patients (TPO mimetic/placebo: 18/14) provided information regarding this outcome (<a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>). </p> <p><a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> defined this outcome as proportion of subject with baseline platelet count &lt; 20 Gi/L and an increase to &gt;20 Gi/L and at least 2 x baseline or a baseline platelet count ≥ 20 Gi/L and an increase to ≥50 Gi/L and at least 2x baseline at any time during treatment with study medication. </p> <p>Ten out of 34 (29%) placebo‐treated patients and 18 out of 64 (28%) eltrombopag‐treated patients showed a platelet response. </p> <p>As these data included both, MDS and AML patients and unfortunately results solely for MDS patients were not reported, thus these findings could not be included. </p> </section> <section id="CD009883-sec-0078"> <h4 class="title">Secondary outcome: Incidence of thrombocytopenia</h4> <p>As thrombocytopenia represents a common symptom for MDS patients and may also occur as a drug‐induced side effect, we judged this outcome as meaningless and therefore did not analyse incidence of thrombocytopenia. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009883-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009883-sec-0079"></div> <p>In the context of Myelodysplastic syndromes (MDS) disease, thrombocytopenia, due to illness or iatrogenically induced, represents a potential life‐threatening condition. Thrombopoietin (TPO) mimetics like romiplostim or eltrombopag might represent a curative option to platelet transfusions, at present considered as the common treatment of thrombocytopenia. Before using these agents outside of clinical trials, it is necessary to illustrate the role and impact of TPO mimetics in the treatment of MDS patients. For that reason we performed this systematic review. </p> <section id="CD009883-sec-0080"> <h3 class="title" id="CD009883-sec-0080">Summary of main results</h3> <p>Our meta‐analysis including six trials and 746 patients results in the following conclusions.</p> <p> <ul id="CD009883-list-0020"> <li> <p>No meta‐analysis was performed for overall survival (OS), our primary outcome, as insufficient data were available. </p> </li> <li> <p>There is little or no evidence for a difference regarding our primary outcome of mortality during study and our secondary outcomes transformation to acute myeloid leukaemia (AML, transfusion requirement, all adverse events and &gt;= grade 3 adverse events and serious adverse events. </p> </li> <li> <p>There is a statistically significance for subgroup differences for serious adverse events when comparing different types of additional agents. Serious adverse events occur more frequently in patients treated with romiplostim monotherapy in comparison to placebo. Serious adverse events were observed less frequently when TPO mimetics were combined with immunomodulatory agents. However, as the number of included patients in the trial giving immunomodulatory agents is very low, certainty of this result remains very low. </p> </li> <li> <p>Treatment with TPO mimetics results in a statistically significant lower incidence of bleeding events compared to placebo. </p> </li> <li> <p>Due to different outcome definitions progression‐free survival (PFS) was not meta‐analysed. Platelet response was not meta‐analysed because no MDS‐subgroup data were available. </p> </li> <li> <p>None of the trials reported health‐related quality of life or duration of thrombocytopenia.</p> </li> </ul> </p> </section> <section id="CD009883-sec-0081"> <h3 class="title" id="CD009883-sec-0081">Overall completeness and applicability of evidence</h3> <p>Six studies, five published in full‐text publications and one published as an abstract, addressed the use of TPO mimetics for MDS patients and included adult patients between 18 and 90 years of age with IPSS low‐, intermediate‐1, intermediate‐2 risk or high‐risk MDS. Except health‐related quality of life and duration of thrombocytopenia, the included trials reported our previously specified protocol outcomes. OS and PFS were only reported in some trials, but could not be included in the meta‐analysis, due to missing data and different outcome definition. The outcome "mortality during study" was analysed as an additional primary outcome. </p> <p>Due to small sample sizes (e.g. <a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a> N = 29; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a> N = 40; <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> N = 32; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a> N = 39;) the included studies do not have adequate power to detect small differences. Moreover, a poor information content of these trials hampered the evaluation of differences in subgroup analyses and therefore a potential heterogeneity in detail. The trials provided sufficient informations in terms of therapy‐related risks (e.g. transformation to AML, transfusion requirement, incidence of bleeding events), but adequate data on the clinical benefit (e.g. OS, AML‐free survival, health‐related quality of life) were lacking. Reported follow‐up were short for some trials: four weeks (<a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>; <a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a>), six months (<a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>; <a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a>), 19 months (<a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a>) and five years (<a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>). Due to the premature study closure of two studies (<a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a>; <a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>), overestimates are imaginable and publication bias might be present, but we have no evidence for this. </p> <p>Currently, there is one ongoing study and one already completed trial, focusing on eltrombopag for patients with MDS. The ongoing study will be completed in 2019; the other trial was completed in 2015, but no results for MDS patients have been published yet. Both trials could help to shed light on the value of eltrombopag in the treatment of MDS patients, as this drug is under‐represented in the meta‐analysis. </p> </section> <section id="CD009883-sec-0082"> <h3 class="title" id="CD009883-sec-0082">Quality of the evidence</h3> <p>Overall, the potential risk of bias of the six included trials with 746 patients is high. All trials were reported to be randomised, double‐blinded and placebo‐controlled and a;; had a registered protocol. Five trials suggested using an interactive voice response system (IVRS) for random sequence generation. Although there was a lack of information regarding allocation concealment and blinding procedures, we did not expect any selection or performance bias. However, three trials were very small, baseline imbalances were reported for two trials. In addition, two studies were stopped prematurely, because outcomes crossed the predefined futility threshold or due to concerns regarding a transient increase in blast cell counts, and as a result the risk for a premature progression to AML. Less outcomes than protocol‐predefined were published in one trial. In summary, this could lead to selection bias and other sources of bias. All trials were sponsored by the pharmaceutical industry. Furthermore, <i>Amgen</i>, the manufacturer of romiplostim, funded four included trials. </p> <p>The quality of evidence for the outcomes number of bleeding events and adverse events is moderate due to high risk of bias and downgraded by one point (small sample sizes and imbalances in baseline characteristics in three trials, premature closure of two trials, selective reporting in one trial). The quality of evidence for the outcomes mortality during study (measured instead of OS) and transfusion requirements is low, due to imprecision through small number of events (downgraded one point) and high risk of bias (downgraded one point). It is very low for the outcomes transformation to AML and serious adverse events, because of very small number of events (downgraded two points), high risk of bis and heterogeneity between trials (downgraded one point). Quality of life was not reported in any of the included trials. </p> </section> <section id="CD009883-sec-0083"> <h3 class="title" id="CD009883-sec-0083">Potential biases in the review process</h3> <p>To avoid potential biases within the review, only randomised controlled trials were observed and the entire processing was edited by two review authors. All conference proceedings (ASH, ASCO, EHA, ESMO) and study registries were searched until May 2017. We expect, that all appropriate studies were identified, all essential data could be acquired and the processing of this meta‐analysis did not introduce bias into this review. </p> <p>As less than 10 trials were included in this meta‐analysis, we were not able to evaluate publication bias and therefore did not generate a funnel plot. By searching all relevant databases and study registries (ISRCTN, EU clinical trials register, Clinicaltrials.gov), we identified one ongoing trial with an estimated completion date in 2019 and one which has already been completed (September 2015), but without publishing results for MDS patients. This may indicate an unexciting result and hence a lack of incentive to publish, but we are awaiting further results of this trial soon. </p> </section> <section id="CD009883-sec-0084"> <h3 class="title" id="CD009883-sec-0084">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD009883-bbs2-0055" title="PricaA , SholzbergM , BucksteinR . Safety and efficacy of thrombopoietin‐receptor agonsits in myelodysplastic syndromes: a systematic review and meta‐analysis of randomized controlled trials. British Journal of Haematology2014;167:626‐38. ">Prica 2014</a> and colleagues analysed the value of TPO mimetics compared to placebo in patients with MDS, <a href="./references#CD009883-bbs2-0023" title="DesboroughM , HadjinicolaouAV , ChaimaniA , TrivellaM , VyasP , DoreeC , et al. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta‐analysis and systematic review. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD012055.pub2; PUBMED: 27797129] ">Desborough 2016</a> and colleagues evaluated alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure. Both reviews included five trials for the comparison TPO mimetics versus placebo for MDS patients or patients with chronic bone marrow failure. We included the same trials, but due to our updated search strategy also the trial by <a href="./references#CD009883-bbs2-0001" title="DickinsonMJ , CherifH , FenauxP , MittlemanM , VermaA , SocorroM , et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016. ">Dickinson 2016</a> and colleagues. Our results are in line with these reviews, also less bleeding events and pointing out the unclear risk of potentially more patients with transformation to AML caused by these agents. As the focus of the <a href="./references#CD009883-bbs2-0023" title="DesboroughM , HadjinicolaouAV , ChaimaniA , TrivellaM , VyasP , DoreeC , et al. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta‐analysis and systematic review. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD012055.pub2; PUBMED: 27797129] ">Desborough 2016</a> review was on alternative agents to platelet transfusions, they assessed different outcomes and also included patients with AML. Moreoever, the authors planned a network meta‐analysis, which they were not able to perform, due to huge inconsistency between trials. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009883-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009883-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009883-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009883-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.1 Mortality during study ‐ all." data-id="CD009883-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.1 Mortality during study ‐ all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.7 Transformation to AML ‐ all." data-id="CD009883-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.7 Transformation to AML ‐ all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.12 Incidence of bleeding events ‐ all." data-id="CD009883-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.12 Incidence of bleeding events ‐ all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 1 Mortality during study ‐ all." data-id="CD009883-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 1 Mortality during study ‐ all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 2 Mortality during study ‐ all (sensitivity analysis, FE model)." data-id="CD009883-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 2 Mortality during study ‐ all (sensitivity analysis, FE model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 3 Mortality during study ‐ different types of thrombopoietin mimetics." data-id="CD009883-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 3 Mortality during study ‐ different types of thrombopoietin mimetics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 4 Mortality during study ‐ different types of additional agents." data-id="CD009883-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 4 Mortality during study ‐ different types of additional agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 5 Mortality during study ‐ different types of MDS risk groups." data-id="CD009883-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 5 Mortality during study ‐ different types of MDS risk groups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 6 Mortality during study ‐ full‐text versus abstract publication." data-id="CD009883-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 6 Mortality during study ‐ full‐text versus abstract publication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 7 Transformation to AML ‐ all." data-id="CD009883-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 7 Transformation to AML ‐ all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 8 Transformation to AML ‐ all (sensitivity analysis, FE model)." data-id="CD009883-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 8 Transformation to AML ‐ all (sensitivity analysis, FE model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 9 Transformation to AML ‐ different types of thrombopoietin mimetics." data-id="CD009883-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 9 Transformation to AML ‐ different types of thrombopoietin mimetics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 10 Transformation to AML ‐ different types of additional agents." data-id="CD009883-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 10 Transformation to AML ‐ different types of additional agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 11 Transformation to AML ‐ different types of MDS risk groups." data-id="CD009883-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 11 Transformation to AML ‐ different types of MDS risk groups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-12.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 12 Incidence of bleeding events ‐ all." data-id="CD009883-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 12 Incidence of bleeding events ‐ all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 13 Incidence of bleeding events ‐ all (sensitivity analysis, FE model)." data-id="CD009883-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 13 Incidence of bleeding events ‐ all (sensitivity analysis, FE model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 14 Incidence of bleeding events ‐ &gt;= grade 3 versus all bleeding events." data-id="CD009883-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 14 Incidence of bleeding events ‐ &gt;= grade 3 versus all bleeding events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 15 Incidence of bleeding events ‐ different types of thrombopoietin mimetics." data-id="CD009883-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 15 Incidence of bleeding events ‐ different types of thrombopoietin mimetics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 16 Incidence of bleeding events ‐ different types of additional agents." data-id="CD009883-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 16 Incidence of bleeding events ‐ different types of additional agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 17 Incidence of bleeding events ‐ different MDS risk groups." data-id="CD009883-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 17 Incidence of bleeding events ‐ different MDS risk groups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 18 Transfusion requirement ‐ all." data-id="CD009883-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 18 Transfusion requirement ‐ all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 19 Transfusion requirement ‐ all (sensitivity analysis, FE model)." data-id="CD009883-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 19 Transfusion requirement ‐ all (sensitivity analysis, FE model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 20 Transfusion requirement ‐ different types of additional agents." data-id="CD009883-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 20 Transfusion requirement ‐ different types of additional agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 21 All adverse events ‐ all." data-id="CD009883-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 21 All adverse events ‐ all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 22 All adverse events ‐ all (sensitivity analysis, FE model)." data-id="CD009883-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 22 All adverse events ‐ all (sensitivity analysis, FE model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 23 All adverse events ‐ different types of thrombopoietin mimetics." data-id="CD009883-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 23 All adverse events ‐ different types of thrombopoietin mimetics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 24 All adverse events ‐ different types of additional agents." data-id="CD009883-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 24 All adverse events ‐ different types of additional agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 25 All adverse events ‐ different MDS risk groups." data-id="CD009883-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 25 All adverse events ‐ different MDS risk groups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 26 Adverse events &gt;= grade 3 ‐ all." data-id="CD009883-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 26 Adverse events &gt;= grade 3 ‐ all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 27 Adverse events &gt;= grade 3 ‐ all (sensitivity analysis, FE model)." data-id="CD009883-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 27 Adverse events &gt;= grade 3 ‐ all (sensitivity analysis, FE model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 28 Adverse events &gt;= grade 3 ‐ different types of thrombopoietin mimetics." data-id="CD009883-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 28 Adverse events &gt;= grade 3 ‐ different types of thrombopoietin mimetics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 29 Adverse events &gt;= grade 3 ‐ different types of additional agents." data-id="CD009883-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 29 Adverse events &gt;= grade 3 ‐ different types of additional agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 30 Adverse events &gt;= grade 3 ‐ different MDS risk groups." data-id="CD009883-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 30 Adverse events &gt;= grade 3 ‐ different MDS risk groups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 31 Serious adverse events ‐ all." data-id="CD009883-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 31 Serious adverse events ‐ all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 32 Serious adverse events ‐ all (sensitivity analysis, FE model)." data-id="CD009883-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 32 Serious adverse events ‐ all (sensitivity analysis, FE model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009883-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/urn:x-wiley:14651858:media:CD009883:CD009883-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_t/tCD009883-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 33 Serious adverse events ‐ different types of additional agents." data-id="CD009883-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 Thrombopoietin mimetics versus placebo, Outcome 33 Serious adverse events ‐ different types of additional agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/media/CDSR/CD009883/image_n/nCD009883-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009883-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Thrombopoietin mimetics compared to placebo for patients with myelodysplastic syndromes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Thrombopoietin mimetics compared to placebo for patients with myelodysplastic syndromes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Adult patients with myelodysplastic syndromes and thrombocytopenia<br/> <b>Setting:</b> Inpatient or outpatient. The duration of studies ranged from four 28‐day cycles to 6 months and &gt; 58 weeks<br/> <b>Intervention:</b> Thrombopoietin mimetics or thrombopoietin plus standard therapy; thrombopoietin mimetics: </p> <p> <ul id="CD009883-list-0001"> <li> <p>romiplostim: 500 µg or 750 µg</p> </li> <li> <p>eltrombopag: 200 mg/day (100 mg/day for East Asians), adjusted by 100 mg increments (50 mg for East Asians) to a maximum 300 mg/day (150 mg/day in East Asias) or 50 mg daily initial dose, adjusted every 2 weeks based on platelet response up to a maximum of 300 mg once daily (150 mg for East Asian patients) for 6 months as an oral tablet </p> </li> </ul> </p> <p><b>Comparison:</b> Placebo or placebo plus standard therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Thrombopoietin mimetics</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall survival</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>282 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As <a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> did not provide 95% CI, data could not be meta‐analysed. </p> <p><a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a>: OS 58‐weeks follow up: 18% of romiplostim patients died and 20.5% of placebo patients (HR 0.86, 95% CI 0.48 to 1.56). </p> <p><a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a>: median OS: 34 weeks for eltrombopag patients and 15.4 weeks for placebo‐treated patients (HR 0.70, CI not provided) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality during study</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.73 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>746<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1; 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>242 per 1.000<br/> (182 to 316) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Transformation to AML</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/> (0.59 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>372<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1.000<br/> (65 to 195) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of bleeding events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/> (0.86 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>390<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>713 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>656 per 1.000</p> <p>(613 to 699)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Transfusion requirement</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/> (0.66 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>358<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>508 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>422 per 1.000<br/> (335 to 534) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01</p> <p>(0.96 to 1.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>390<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>912 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>921 per 1.000<br/> (875 to 976) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.54 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>356<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2 ,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>387 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>344 per 1.000<br/> (209 to 564) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Small number of events (&lt;200) resulting in downgrading 1 point due to imprecision </p> <p><sup>2</sup> High risk of bias due to small sample sizes and imbalances in baseline characteristics in three trials, premature closure of two trials, selective reporting in one trial, and industrial sponsorship </p> <p><sup>3</sup> Very small number of events (&lt;50) resulting in downgrading 2 points due to imprecision </p> <p><sup>4</sup> Heterogeneity between studies resulting in downgrading in 1 point </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Thrombopoietin mimetics compared to placebo for patients with myelodysplastic syndromes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009883-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009883-bbs2-0002" title="GiagounidisA , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120(12):1838‐46. GiagounidisA , MuftiGJ , KantarjianHM , FenauxP , SekeresMA , SzerJ , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011. KantarjianH , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , KuendgenA , et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016. KantarjianHM , MuftiG , FenauxP , SekeresM , SzerJ , PlatzbeckerU , et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553. KantarjianHM , MuftiGJ , FenauxP , SekeresMA , SzerJ , PlatzbeckerU , et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012. SekeresM , GiagounidisA , KantarjianHM , MuftiGJ , FenauxP , JiaC , et al. Development and validation of a model to predict response to romiplostim in patients with lower‐risk myelodysplastic syndromes (MDS). Blood2012;120:1838‐46. ">Giagounidis 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009883-bbs2-0003" title="GreenbergPL , Garcia‐ManeroG , MooreM , DamonL , RobozG , HuK , et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia &amp; Lymphoma2013;54(2):321‐8. GreenbergPL , Garcia‐ManeroG , MooreMR , DamonLE , RobozGJ , WeiH , et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood2009;114:Abstract: 1769. ">Greenberg 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009883-bbs2-0004" title="KantarjianH , GilesF , GreenbergP , PaquetteR , WangE , GabriloveJ , et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. KantarjianHM , GilesFJ , GreenbergPL , PaquetteRL , WangES , GabriloveJL , et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116(17):3163‐70. ">Kantarjian 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009883-bbs2-0005" title="PlatzbeckerU , WongRS , VermaA , AbboudC , AraujoS , ChiouTJ , et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology2015;2(10):e417‐26. [PUBMED: 26686043] PlatzbeckerU , WongRSM , AraujoS , FeigertJ , BennettJ , MessamC , et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015. PlatzbeckerU , WongRSM , VermaA , AbboudCN , AraujoS , ChiouTJ , et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21). WroblewskiS , ShiW , MuddP , AivadoM . Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15. ">Platzbecker 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009883-bbs2-0006" title="LyonsRM , LarsonRA , KosmoMA , GandhiSL , DelongCM , DreisbachL , et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770. WangES , LyonsRM , LarsonRA , GandhiS , LiuD , MateiC , et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology &amp; Oncology2012;5:71. ">Wang 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo = 83</p> <p>TPO mim. = 167</p> <p>(PBO / TPO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo = 14</p> <p>TPO mim. = 15</p> <p>(PBO / TPO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo = 13</p> <p>TPO mim. = 27</p> <p>(PBO / TPO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo = 14</p> <p>TPO mim. = 18</p> <p>(PBO / TPO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo = 9</p> <p>TPO mim. = 28</p> <p>(PBO / TPO)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 / 157 <sup>2)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 / 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 / 27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 / 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 / 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 1 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 2 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 3 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 / 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 / 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥<b>Grade 3 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 / 13 <sup>9)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 4 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 5 AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 / 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 / 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 /13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peripheral oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Contusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 / 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash &amp; hypersensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 / 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain in extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IP‐related adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 14 <sup>6)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious AE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 / 67<sup>1)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 / 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 / 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 9 <sup>12)</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 / 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 / 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ Grade 3 bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haematoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Febrile neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myelofibrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>3)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythema nodosum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypokalemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IP‐related SAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 2 <sup>7)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cerebrovascular accident</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endocarditis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary artery thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1 <sup>4)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fungal pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutropenic sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 / 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n. r.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deaths</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 / 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 1 <sup>5)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 / 0<sup>8)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 / 1 <sup>10)</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE leading to withdrawal</b> </p> <p><b>or IP discontinuation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 / 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 / 3 <sup>11)</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Legend:<i><b>AE</b> </i> adverse event; <i><b>IP</b> </i> investigational product; <i><b>n. r.</b> </i> not reported </p> <p><sup>1)</sup>Serious AE related to romiplostim: 12 patients ( increased myeloblast count, colon cancer, deep vein thrombosis, extramedullary haemopoiesis, leukocytosis, myelofibrosis, pneumonia, pyrexia, splenic infarction, transient ischaemic attack, type 2 diabetes mellitus) </p> <p><sup>2)</sup>Adverse event in both study arms: Epistaxis, hematoma, petechiae </p> <p><sup>3)</sup>Two romiplostim‐treated patients had myelofibrosis. One patient had disease progression and was reported to have grade 3 bone marrow fibrosis on day 35 of treatment. This event was reported being related to romiplostim. The second patient had a history of myelofibrosis and progressed to grade 2 bone marrow fibrosis on day 71 and grade 3 bone marrow fibrosis on day 99 of treatment. None of these event were considered related to romiplostim treatment. </p> <p><sup>4)</sup>One patient (7%) in the romiplostim group; pulmonary artery thrombosis was reported as treatment‐related serious adverse event </p> <p><sup>5)</sup>Three deaths occurred during treatment period. None was considered related to treatment, although neutropenic sepsis was considered related to decitabine. No deaths occurred during extension period. One death was reported in the romiplostim group who died from cholecystitis ≥30 days after last dose of romiplostim </p> <p><sup>6)</sup>All treatment‐related adverse events were grade 1 or 2, except for grade 3 arthralgia in one patient in the romiplostim 500 µg group and one patient with grade 3 rash in the 750 µg group. </p> <p><sup>7)</sup>Three patients had treatment‐related serious adverse events, two in the placebo group ( myelofibrosis and erythema nodosum) and one patient with grade 3 rash in the romiplostim 750 µg group. </p> <p><sup>8)</sup>One patient died from fungal pneumonia and one from endocarditis. </p> <p><sup>9)</sup>The most common ≥ grade 3 AE in the eltrombopag vs PBO groups were: febrile neutropenia (6% / 29%), anaemia (11% / 14%), pneumonia (11% / 14%) and sepsis (11% / 14%). </p> <p><sup>10)</sup>One patient in the 750µg romiplostim group died during the extension period from intestinal obstruction, which was not considered related to romiplostim. </p> <p><sup>11)</sup>Adverse events leading to study withdrawal were pancytopenia, asthenia, and cerebrovascular accident in the placebo group; pancytopenia and rash in the romiplostim 500µg group; and thrombocytopenia in the 750µg group. Only cerebrovascular accident in the placebo group was considered related to IP. </p> <p><sup>12)</sup>Only two serious AE were considered related to treatment: Cerebrovascular accident in one patient in the placebo group and worsening thrombocytopenia in one patient in the romiplostim 500µg group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/full#CD009883-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009883-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Thrombopoietin mimetics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality during study ‐ all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality during study ‐ all (sensitivity analysis, FE model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.74, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality during study ‐ different types of thrombopoietin mimetics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Romiplostim</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.33, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Eltrombopag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.73, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality during study ‐ different types of additional agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Thrombopoietin mimetic monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.51, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Plus hypomethylating agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.23, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Plus immunomodulatory agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mortality during study ‐ different types of MDS risk groups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Low risk &amp; intermediate‐1 risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.33, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Intermediate‐2 risk and high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.25, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Mixed risk group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.81, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mortality during study ‐ full‐text versus abstract publication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 full‐text publication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.48, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 abstract publication Mixed risk group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.81, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Transformation to AML ‐ all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.59, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Transformation to AML ‐ all (sensitivity analysis, FE model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Transformation to AML ‐ different types of thrombopoietin mimetics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.59, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Romiplostim</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.55, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Eltrombopag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.37, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Transformation to AML ‐ different types of additional agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.59, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Thrombopoietin mimetic monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.58, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Plus hypomethylating agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.17, 5.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Plus immunomodulatory agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Transformation to AML ‐ different types of MDS risk groups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.59, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Low risk &amp; intermediate‐1 risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.55, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Intermediate‐2 risk and high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.37, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Incidence of bleeding events ‐ all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Incidence of bleeding events ‐ all (sensitivity analysis, FE model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Incidence of bleeding events ‐ &gt;= grade 3 versus all bleeding events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 &gt;= grade 3 bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.10, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Incidence of bleeding events ‐ different types of thrombopoietin mimetics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Romiplostim</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Eltrombopag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.10, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Incidence of bleeding events ‐ different types of additional agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Thrombopoietin mimetics monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Plus hypomethylating agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.54, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Plus immunomodulatory agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [0.50, 25.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Incidence of bleeding events ‐ different MDS risk groups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Low risk &amp; intermediate‐1 risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Intermediate‐2 risk and high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.10, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Transfusion requirement ‐ all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.66, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Transfusion requirement ‐ all (sensitivity analysis, FE model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.67, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Transfusion requirement ‐ different types of additional agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.66, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Thrombopoietin mimetics monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.68, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Plus hypomethylating agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.43, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Plus immunomodulatory agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.33, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 All adverse events ‐ all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 All adverse events ‐ all (sensitivity analysis, FE model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.94, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 All adverse events ‐ different types of thrombopoietin mimetics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Romiplostim</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Eltrombopag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 All adverse events ‐ different types of additional agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Thrombopoietin mimetics monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.96, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Plus hypomethylating agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.92, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Plus immunomodulatory agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.41, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 All adverse events ‐ different MDS risk groups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Low risk &amp; intermediate‐1 risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Intermediate‐2 risk and high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse events &gt;= grade 3 ‐ all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse events &gt;= grade 3 ‐ all (sensitivity analysis, FE model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.72, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse events &gt;= grade 3 ‐ different types of thrombopoietin mimetics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Romiplostim</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.63, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 Eltrombopag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.74, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse events &gt;= grade 3 ‐ different types of additional agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 Thrombopoietin mimetics monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.74, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 Plus hypomethylating agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.27, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3 Plus immunomodulatory agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.60, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse events &gt;= grade 3 ‐ different MDS risk groups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 Low risk &amp; intermediate‐1 risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.63, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 Intermediate‐2 risk and high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.74, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Serious adverse events ‐ all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.54, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Serious adverse events ‐ all (sensitivity analysis, FE model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.85, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Serious adverse events ‐ different types of additional agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.54, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 Thrombopoietin mimetics monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.01, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Plus hypomethylating agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.57, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 Plus immunomodulatory agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.24, 0.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Thrombopoietin mimetics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009883.pub2/references#CD009883-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009883.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009883-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009883-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD009883-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD009883-note-0008">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009883\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009883\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009883\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009883\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009883\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009883.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009883.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009883.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009883.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009883.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725194025"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009883.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725194029"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009883.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e75479b8c1be5',t:'MTc0MDcyNTE5NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 